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Abstract  
 
 
 
The aim of this research project has been focused on improving diagnosis, therapy, and surgery by 
using new patented technologies and materials.  
The first technology that has been examined in it has been SynDiag – a new software patented at 
Polytechnic School – University of Turin that represent the first step of a new concept of accurate 
diagnosis without using the X-ray technology but only ultrasounds. The output will be no more 
qualitative but quantitative and can be obtained from an existing full console machine connected to 
a 3D transducer with the result of keeping the costs to the minimum.  
The second technology is a patent coming from the Russian Federation and called Proton Therapy. 
This new technology is based on the acceleration of both protons and neutrons and can be tailored 
on every human (child, adults, young, elderly, slim etc.…) and been effective on the detection and 
dissolution of brain cancer on which it is not possible to perform a surgery.  
Another problem that has been explored is the big problem of the antibiotic resistance and the most 
dangerous superbugs (ranked by the WHO in February 2017) and their biofilms currently giving 
infections and post-surgery complication ending into an unlucky and poor prognosis. A solution has 
been found with evidences of efficacy cooperating with the USA, Germany, Australia, and New 
Zealand.  
Concerning the materials, the research has been focused on medical application of polyurethane – a 
type of PU has been synthesized at Polytechnic School – University of Turin to study the 
complexity of the human ageing and trying to make a cardiac tissue model young and aged 
avoiding the use of the animal model. 
Finally, a medical polyurethane (PU) has been treated to become an antimicrobial or self-sterilizing 
surface where superbugs cannot colonize, survive or spread to control nosocomial infections and 
prevent the misuse of antibiotics, and consequently try to overcome the big problem of the 
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antibiotic resistance. This research project origins from a bigger research area of the University 
College London that involves different knowledge and experience coming from the Medical School 
and the Dental Hospital, the School of Engineering, the Chemistry Dept. and the School of 
Pharmacy. The first prototype was a catheter containing a crystal violet and golden nanoparticles 
(NPs) solution that effectively kills E. Coli, MRSA and Candida albicans. The antimicrobial 
material of this dissertation is intended as an improvement of the existing one – most of the 
procedure has been changed and the solution was obtained using crystal violet and silver NPs but 
also silver NPs only. Silver nanoparticles showed the evidence to kill P. aeruginosa while staying 
inside the bulk of the material avoiding superficial oxidation processes. The coating material 
obtained can reduce bacteria biofilm caused diseases in humans and is on its way to be patented.    
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Chapter 1 
New Technologies to improve 
diagnosis, therapy and surgery 
 
 
1.1. SynDiag  
1.1.1.  INTRODUCTION                                          
The name of this new Italian patent is SynDiag that means “syndrome diagnosis” and it is focused 
on the detection of foetus facial dysmorphisms by using the ultrasound imaging technology.    
Ultrasound is worldwide the most adopted and the safest screening method for prenatal imaging and 
diagnosis of possible fetal pathologies. It allows physicians to visualize in a non-harmful way the 
fetus development, despite the sensitiveness of ultrasound to scattering noise. Indeed, this 
represents the main drawback of the technology, impeding easy development of fully automatic 
images post-processing, which usually requires some level of human intervention1. This is true also 
for newest 3D ultrasound machines2, whose output is a qualitative render obtained from registered 
bi-dimensional ultrasound scans.  
In this manuscript, it is presented a recently developed algorithm for automatic extraction of a 
three-dimensional surface of fetus face from a registered stack of bi-dimensional ultrasound scans3. 
It operates without human intervention, elaborating input data in the standard DICOM format with a 
two-steps statistical analysis based on volumetric histogram processing and 2D segmentation. It 
outputs a quantitative triangular mesh in PLY format, ready for further mathematical analysis.  
By way of method validation and as an example of the application, it is developed a diagnosis tool, 
based on the former elaboration, which succeeded in discriminating labio-schisis manifesting 
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individuals from healthy individuals4. Being a stochastic algorithm based on unsupervised 
clustering, its feasibility is tested upon a small set of available real fetus data and then extensively 
studied with adult individuals’ dataset, known as Bosphorus5. The algorithm maps the individual's 
surface with geometrical descriptors useful to identify the face's landmarks, i.e. pronasion and 
labrum superior, and compute a distance measure between each faces couple. The algorithm 
correctly identifies left- and right-sided cleft lips, providing the physicians with a probability of 
pathology affection and supporting decision making.  
Since the method is fully automatic and pathology independent, it allows to easily populate large 
database of quantitative fetus' faces individuals, enabling objective pathologies to be characterized 
and normotypes defined.  
Consequently, for all the characteristics listed above, SynDiag can be considered as “the new 
concept of prenatal diagnosis”.  
 
1.1.2.  EXPERIMENTAL                                          
The SynDiag project started in 2012 as a cooperation between the Polytechnic School – University 
of Turin and the Polytechnic School – University of Milan with the purpose to help 10 million of 
newborns. In fact, it is nowadays statistically clear that only in Europe, more than 2% (10M) of the 
population suffers of congenital malformations. Unfortunately, a percentage like the 80% of 
congenital anomalies are not associated to a specific manifestation risk (e.g. it cannot be detected 
examining the parents) and only 52% of cases can be diagnosticated by prenatal diagnosis6.    
 
 
Figure 1. Congenital anomalies: foetus facial dysmorphisms are 
represented in orange colour. Courtesy of Arch. Stefano Fantucci 
– Polytechnic School – University of Turin.  
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It is clear that prenatal diagnosis is essential to rule out diseases that endangers the child’s life at 
birth and to prevent the pregnant woman from giving birth in facilities that do not have a pediatric 
surgery department. It is also clear that ultrasound is a non-invasive test that is usually performed 
from the 5th month when the foetus dimensions allow an acceptable diagnostic definition7.  
The existing problem is represented by two conditions: the first one known as labio-schisis or cleft 
lip and the second one known as Foetal Alcohol Syndrome (FAS) that is a condition which is linked 
to drinking alcohol in pregnancy which affects the way a baby’s brain develops. This condition was 
first identified in the United States of America in 1973 and its severity is thought be related to how 
much alcohol a mother drank during pregnancy8-9. Children with FAS have problems with their 
neurological development, abnormal growth, and have characteristic facial features that result from 
their foetal exposure to alcohol. Neurological problems are caused by damage to the central nervous 
system (brain and spinal cord). The problems experienced are likely to change as an infant grows up 
and different problems may be seen at different stages of development, from childhood, 
adolescence, and into adulthood10-13. The labio-schisis is explained in the following images.  
 
 
 
 
 
 
Figure 2. Clefts lips in children before and after the surgery. Courtesy of 
Arch. Stefano Fantucci – Polytechnic School – University of Turin. 
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 Figure 4. The Foetal Alcohol Syndrome (FAS) in children in the past. Source: PubMed – NCBI.  
 
Figure 3. An example of cleft lip surgery: it is clearly visible the little scar on the child’s face. 
Courtesy of Arch. Stefano Fantucci – Polytechnic School – University of Turin. 
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The SynDiag project: from September 2012 to January 2013, 30 three-dimensional volumes of 30 
fetuses at 22 – 32 weeks’ gestation were acquired. Written consent was obtained from the parents 
for publication of clinical details, clinical images, and videos. Principles outlined in the Declaration 
of Helsinki have been followed. Among these acquisitions, five were selected and processed for the 
purposes of the study. The remaining ones were excluded due to high noise or practical 
“inconveniences” such as baby’s hands on face, or simply too much inaccuracy in the scanning 
process. The ultrasound equipment was a Voluson system (GE Healthcare, Wauwatosa, WI, USA), 
with a RAB 4–8 (real time 4D convex transducer probe). The GE RAB 4–8 has a frequency range 
of 4 MHz to 8 MHz and is used for OB applications (Footprint 63.637.8 mm, FOV 70°, V 
85°70°). The procedure is completely automatic, enabling fully unattended segmentation. This 
leads to the possibility of creating a large database of 3D facial point clouds, like the ones required 
for morphological studies through statistical analyses, without the necessity of human intervention. 
The algorithm works with standard protocols and file format (DICOM as input and any mesh file 
format as output), so it is completely platform-independent. The same idea of algorithm may also be 
extended to internal tissues segmentation to reach a complete 3D model of the fetuses’ face and of 
other organs (e.g. the heart). Furthermore, it can be extended to other applications of ultra sound 
imaging and for working with different 3D imaging techniques (CT or MRI), taking advantage, in 
this case, of the absence of the speckle noise effect14.  
Figure 5. The Foetal Alcohol Syndrome (FAS) in children at present. Source: Google Library.  
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The SynDiag patent is a procedure for medical images processing, aimed to the detection of oro-
facial dysmorphisms (e.g. Labio/Palato-schisis). The value of this new procedure is that it can easily 
overcome the limits of the current ultrasound imaging technology that are based on a qualitative 
rendering without a quantitative elaboration with the consequence that only expert physicians can 
recognize an abnormal fetus development. The result unfortunately is that many of them are not 
currently diagnosticated with the consequences illustrated in the above pictures14-15.  The SynDiag 
procedure allows a quantitative analysis and a pre-birth accurate and fast diagnosis becoming a 
really good support for physicians’ decisions. It is a unique procedure because is based on an 
ultrasound imaging technology that is a fast and non-invasive method and allows diagnosis as early 
as possible, and in addiction to this it can outputs 3D quantitative images from registered 2D 
ultrasound scans, consequently it is affordable if compared with existing 3D ultrasound imaging 
devices because it is a plug-in software adaptable to any full console machine on the market15-16.        
 
 
 
 
 
Figure 6. The Ultrasound device market – the importance and impact of the growing global ultrasound 
imaging technology market. Courtesy of Arch. Stefano Fantucci – Polytechnic School – University of Turin. 
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The SynDiag method and performance: in the pre-processing phase the DICOM file is initially 
imported as a stack of 2D planar slices. This can be done in any of the three coordinate directions, 
as the algorithm does not depend on the position of the foetus. Ultrasound wave scattering damages 
the images by introducing a type of noise called speckle, so in order to enhance segmentation 
performance, noise is removed through filtering in the first phase. Current algorithms performing 
this task are based on statistical analysis, inverse PSF filtering, and log separation. In the SynDiag 
algorithm, a standard 3D low-pass Gaussian filtering was accurate enough for a preliminary 
speckles removal. After this pre-processing step, the image improves in terms of quality and helps 
to enhance the performance, although it is not yet clean enough for achieving complete surface 
extraction. The second phase is the surface reconstruction through 3D histogram processing. Both 
volume and surface reconstruction are demanding tasks, due to the coexistence of different tissues 
in the same image (from both mum and foetus). Edge extraction is even trickier when the foetuses’ 
head lays directly on the mother’s uterus, hence in this scenario, the two tissues are virtually 
merged from the ultrasound imaging standpoint. To overcome this problem the SynDiag algorithm 
has been developed, it is based on a statistical analysis of local and 3D histograms that 
automatically combine slice and volumetric processing. The following phase is known as data 
fusion. Potentially, the model extracted after the second phase is complete enough to recognize the 
Figure 7. The SynDiag patent, courtesy of Dr Giulio Cattano – Polytechnic School – University of Turin. 
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shape of the foetuses’ face, but to enhance detection and improve the accurateness a data fusion step 
has been added to the workflow. The previous 3D shape extraction from all three directions has 
been repeated by permuting the dimensions of the DICOM stack, and combine the extracted 
surfaces evaluating the logical AND of the three binary arrays. Consequently, this operation 
increases the robustness of the SynDiag algorithm. Moreover, this kind of procedure heavily 
reduces the number of false positives (i.e. edges that do not actually belong to the desired surface). 
After the data fusion, the output is fairly “clean”, but can still be refined by using a post-processing 
phase in which the three main operations: edge detection, island removal and point cloud and mesh 
generation take place.  Finally, the surface is reconstructed by the Poisson surface reconstruction 
algorithm, exploiting the publicly-available pointCloud2rawMesh function and the resulting 
vertices and faces are written in the final PLY file16-24.  The resulting 3D quantitative model (a 
mathematical object) has also been 3D printed as shown in the following images.        
 
 
  
Figure 8. The 3D quantitative model.  
 
The 3D printed foetus face (in white 
colour), it is the 3D printed version of the 
quantitative model produced with MeshLab 
that is the triangular mesh obtained by the 
SynDiag algorithm.  
 
The surface of the foetus face (in yellow 
colour) is a mathematical elaboration of it. 
Courtesy of Dr Daniele Conti – SynDiag 
inventor. 
Figure 9. 3D qualitative images: these images are three examples of 3D ultrasound images exported by using 
ultrasound full console machines currently used in clinics and hospitals. These images have the best achievable 
quality nowadays, but they cannot be 3D processed and consequently they cannot give a printable 3D model 
because they are only qualitative. Courtesy of Dr Daniele Conti – SynDiag inventor.    
17 
 
 
Figure 10. The SynDiag methods and performance, courtesy of Dr Daniele Conti – SynDiag inventor.  
 
 
Figure 11.  The SynDiag algorithm workflow, courtesy of Dr Daniele Conti – SynDiag inventor.    
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1.1.3.  CONCLUSION      
The SynDiag project started in 2012 and was patented at Polytechnic School – University of Turin 
during the academic year 2015 – 2016 when I joined the project. Working at this project really 
challenged me as I helped my colleagues with my clinical and pharmaceutical background to 
improve our new patent in the field of foetal diagnosis by 3D ultrasound imaging technology. I had 
to fully understand the algorithm methods and performances working closely with the inventors of 
it. Then I had to collect from gynaecologists and physicians every daily clinical problem related to 
the pre-natal diagnosis of foetuses’ malformations by using the existing ultrasound imaging 
technology. At the end I understood how to tailor the SynDiag algorithm according to the clinical 
needing, and consequently how was its own potential in the ultrasound devices market. In my 
opinion the great advantage of this new technology is that the method automatically extracts 
relevant 3D information of the foetuses’ face from a set of planar 2D ultrasound slices, outputting a 
high-resolution mesh of the facial surface. It is very easy to use by physicians, also by ones at the 
beginning of their career, because the method is fully automatic. In addition to this, the whole 
procedure has been designed and tested with DICOM files as input and a triangular mesh in PLY 
files as output to achieve the maximum interoperability. This algorithm has also been implemented 
using MATLAB® and it is easily portable to any other language. In conclusion, I can confirm that 
SynDiag has been appreciated across the world (U.S.A., Australia, Singapore, Russian Federation, 
UAE, and Europe).   
 
1.1.4.  ACKNOWLEDGEMENTS   
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working with me at the SynDiag patent. I am also grateful to gynaecologists of S. Anna University 
Hospital of Turin and some colleagues from the Royal Pharmaceutical Society of Great Britain for 
their kind help and contribution.             
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1.2.  Proton Therapy  
1.2.1.  INTRODUCTION                                          
In the field of medical procedures, Proton Therapy is a type of external beam radiotherapy that uses 
a beam of protons to irradiate diseased tissue, most often in the treatment of cancer. It is also called 
proton beam therapy, it painlessly delivers radiation through the skin from a machine outside the 
human body. Protons can be accelerated inside a machine called synchrotron or cyclotron that 
speeds up the protons, the speed determines the energy level. At high energy, protons can destroy 
cancer cells because high-energy protons can travel deeper in the body than low-energy ones. With 
proton therapy, radiation does not go beyond the tumour. In contrast, with photon-based external-
beam radiation therapy, x-rays continue depositing radiation as they exit the human body. This 
means that the radiation leaving the body may damage nearby healthy tissue and that damage can 
cause side effects. The chief advantage of proton therapy over other types of external beam 
radiotherapy is that as a charged particle, the dose is deposited over a narrow range and there is 
minimal exit dose. These charged particles damage the DNA of cells, ultimately killing them or 
stopping their reproduction. Cancerous cells are particularly vulnerable to attacks on DNA because 
of their high rate of division and their reduced abilities to repair DNA damage. Some cancers with 
specific defects in DNA repair may be more sensitive to proton radiation. [ ]  Furthermore, the dose 
delivered to tissue is maximized only over the last few millimetres of the particle’s range; this 
maximum is called the Bragg peak, often referred to as the SOBP (the SOBP is the sum of several 
individual Bragg peaks at staggered depths). To treat tumours at greater depths, the proton 
accelerator must produce a beam with higher energy, typically given in eV or electron volts. 
Accelerators used for proton therapy typically produce protons with energies in the range of 70 to 
250 MeV. Adjusting proton energy during the treatment maximizes the cell damage the proton 
beam causes within the tumour. Tissue closer to the surface of the body than the tumour receives 
reduced radiation, and therefore reduced damage. Tissues deeper in the body receive very few 
protons, so the dosage becomes immeasurably small. In most treatments, protons of different 
energies with Bragg peaks at different depths are applied to treat the entire tumour. The total 
radiation dosage of the protons is called the spread-out Bragg peak (SOBP). It is important to 
understand that, while tissues behind (or deeper than) the tumour receive almost no radiation from 
proton therapy, the tissues in front of (shallower than) the tumour receive radiation dosage based on 
the SOBP.  [w ] After the end of the Second World War, building on discoveries made during work 
on the Manhattan Project and other activities, a group of scientists and physicists developed particle 
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accelerators of much higher energy and began applying what they had learned to help benefit 
mankind. They focused on the application of nuclear medicine for diagnostic purposes and the 
treatment of certain diseases. One particular interesting possibility had to do with improving the 
treatment of cancerous tumours, especially those previously unreachable or not treatable without 
inducing significant damage to healthy surrounding tissues. The first suggestion that energetic 
protons could be an effective treatment method was made by Robert R. Wilson in a paper published 
in 1946 while he was involved in the design of the Harvard Cyclotron Laboratory. Today the larger 
proton therapy centre in the world is the Roberts Proton Therapy Center in Philadelphia, PA (USA).    
This centre is a part of Penn’s Abramson Cancer Center, University of Pennsylvania Health System.  
In August 2013, the UK government confirmed that £250 million would be made available to build 
two UK proton therapy centres – one at the Christie Hospital in Manchester, the other at UCL 
Hospital in London.  They’re due to open in 2018, and there’s also an option on the table to have a 
third facility in Birmingham at some point in the future. This is a big sum of money for just two 
treatment centres that are expected to treat around 1,500 patients per year between them – many 
more people than are currently sent abroad (mainly in the USA) for proton therapy.  
Another centre of excellence for both proton therapy and neutron therapy, is located in Obninsk, 
Kaluga Oblast (Russia) at about 2 hours by car from Moscow airport Domodedovo (about 110 km 
southwest of Moscow), where is also based the World’s First Nuclear Power Plant since 27 June 
1954. The nuclear reactor, used to generate electricity, heralded Obninsk's new role as a major 
Soviet scientific city, a status it retains in the Russian Federation where it carries the sobriquet of 
First Russian Science City.  In Obninsk is based the Medical Radiological Research Center A.F. 
Tsyba - a branch of the federal state budgetary institution "National Medical Research Center for 
Radiology" of the Ministry of Health of the Russian Federation (the Tsyba MSC - a branch of the 
NMI of Radiology of the Ministry of Health of Russia) that is one of the oldest radiological centers 
in Russia. The MRRC A.F. Tsyba, originally was the Institute of Medical Radiology of the 
Academy of Medical Sciences of the USSR and, was founded in 1962 to develop and improve 
methods of radiation diagnosis and radiation therapy, prevent, and treat radiation damage, and study 
the biological and medical effects of ionizing radiation. The Center is the head on the problem of 
radiology and radiation medicine, the leading institution in the Russian Federation to develop and 
apply high-tech radiological methods for the diagnosis and treatment of patients with oncological 
and non-oncological diseases. The basis of most of the Center's development of methods for 
treating patients is the principles of increasing the effectiveness of treatment, organ preservation 
and improving the quality of life. The Center's advantage is an integrated approach that allows to 
21 
 
conduct necessary examinations and treatment and to provide the patient with access to innovative 
technologies for the prevention, diagnosis, and treatment of malignant neoplasms. The staff of the 
Center consists of 1779 people of which about 310 researchers (mainly physicists), including about 
59 doctors.[ ]       
 
1.2.2.  EXPERIMENTAL                                          
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1.2.3.  CONCLUSION   
…………….    
In my opinion the great advantage of this technology …..  
Konstantin Eduardovich Tsiolkovsky, known also as K. E. Tsiolkovskii, Jurij Alekseevič Gagarin 
and Stanislav Evgrafovič Petrov.  
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Figure. The monument at Konstantin Eduardovich 
Tsiolkovsky outside the Brisbane Planetarium in 
Brisbane – Queensland – Australia.  
(International Conference: Innovate Medicine, 29th–
30th November 2017 – Brisbane).  
The statue, by Sergei Bychkov, was donated to 
Queensland during Russia Week in Australia in 
2007, the 150th anniversary of the birth of 
Tsiolkovsky. Source: Google Library.  
Figure. The monument at Konstantin 
Eduardovich Tsiolkovsky in Obninsk – 
Kaluga – Russia (own pictures). 
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Chapter 2 
New Materials to improve diagnosis, 
therapy and surgery 
 
 
2.1. A new polyurethane for an in vitro model of the 
cardiac tissue  
2.1.1. INTRODUCTION  
The aim of this work is firstly to overcome the current lack of models for the study of the 
physiological conditions through the development of an in vitro dynamic model, able to reproduce 
the myocardial tissue. The idea to develop alternatives methods to the practice of animal 
experimentation was officially presented to the European Parliament on 26th June 2013. The way to 
proceed will be to make non-animal alternative methods, wherever applicable, compulsory, and to 
encourage their further development, in a concerted drive towards the rapid abolition of the useless 
and risky practice of animal experimentation. The practice of animal experimentation and testing 
have never formally undergone the process of "validation", which is currently required of all new 
testing methods. Polyurethanes today have the realistic potential to be advantageous materials due 
to their high versatility that, according to the selected starting reagents, allows to adapt their 
physical, thermal, mechanical, and biological properties to the final application.  
To satisfy the target an elastomeric biodegradable polyurethane (K-BC 2000) was synthesized 
through a two steps procedure starting from poly--caprolactone diol (Mn = 2000Da), 1,4-butane 
diisocyanate and L-lysine ethyl ester. Then this polyurethane was processed via Thermally Induced 
Phase Separation (TIPS) under application of a cooling gradient in order to obtain oriented fibers 
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texture, like the cardiac muscle tissues topography. Polyurethane scaffolds obtained with TIPS were 
functionalized with fibronectin, one of the main components of the cardiac ECM proteins. The 
functionalization was performed by plasma treatment with argon and acrylic acid, followed by the 
activation of carboxylic groups by N'-(3-dimethylaminopropyl)-N-ethylcarbodiimide in 
combination with N-hydroxysuccinimide, and the coupling with fibronectin. The constructs were 
characterized by SEM, contact angle, XPS and mechanical test, showing mechanical properties and 
morphology similar to those of native tissue (Fig.). Functionalized scaffolds were seeded with 
cardiac cells prepared from neonatal Sprague-Dawley rats. To evaluate the cardiomyocyte self-
beating activity, scaffolds were analyzed from four days after cell seeding every two days, by using 
fluorescent microscopy. Time lapse analysis demonstrated that cells beat synchronously from day 7 
and for over 50 days. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure .  The SEM micrograph of my scaffold.   
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2.1.2.  EXPERIMENTAL      
The MIND project started in 2010, it was fully financed by the Italian Ministry of Education 
(MIUR) and it involved five Italian universities: Polytechnic School – University of Turin, 
Polytechnic School – University of Milan, University of Turin – Molecular Biotechnology Center, 
University of Genoa – Dibris Dept., CNR of Pisa – Institute of clinical physiology and University 
of Rome – Biomedical campus. The MIND project aims at overcoming the current lack of models 
for the study of the physiological conditions associated with aging through the development of in 
vitro dynamic models, able to reproduce the physio-pathological conditions of aged tissues, while 
respecting the principle of animal testing. [ ] Polyurethanes today have the realistic potential to be 
advantageous materials due to their high versatility that, according to the selected starting reagents, 
allows to adapt their physical, thermal, mechanical and biological properties to the final application. 
A new elastomeric biodegradable polyurethane for an in vitro model of the cardiac tissue was 
synthesized and processed in order to obtain oriented fibers texture, like the cardiac muscle tissues 
topography. [ ] 
Materials and methods: It is well known the importance of reproducing the mechanical anisotropy 
of cardiac tissue. The application of isotropic scaffolds for the regeneration of anisotropic tissues 
might confer isotropic properties to the newly formed tissue that prevent its structural and 
mechanical integration in the native environment. [ ]     
 
 
     
 
 
 
 
 
 
 
 
Figure .  The Cardiac tissue model.   
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The elastomeric biodegradable polyurethane (acronym K-BC 2000) used in this work was 
synthesized through a two steps procedure starting from14g of PCL or poly--caprolactone diol 
(Mn = 2000 Da), 2,014g of 1,4-butanediisocyanate and 1,776g of L-lysine ethyl ester (as chain 
extender) as shown in the picture below. Solvents used for the synthesis: DCE anhydrous, DCE, 
DMF and methanol. All the ingredients have been purchased from Sigma-Aldrich®.  
 
 
 
 
 
 
 
 
 
 
 
 
After the PU synthesis, the following step has been the scaffold fabrication by using a technique 
called Thermally Induced Phase Separation (TIPS) under application of a cooling gradient.  
 
 
 
 
 
 
 
Figure  . The PU synthesis through a 
two steps procedure and the mechanical 
properties it aims to reproduce.   
  
 Figure  . The Scaffold Fabrication (morphology).  
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The final step has been the scaffold functionalization with fibronectin, one of the main components 
of the cardiac ECM proteins. It has been performed through a plasma treatment with argon and 
acrylic acid, followed by the activation of carboxylic groups by using 5mg of EDC or N'-(3-
dimethylaminopropyl)-N-ethylcarbodiimide in combination with 1,25mg of NHS or N-
hydroxysuccinimide for 1ml of water solution (pH 5), and finally coupling with 5mg of human 
fibronectin protein (it has been purchased from YO Proteins, Sweden) in 5ml PBS solution at 37°C 
(pH 5), filtered through a 0,m membrane filter. All details are shown in the following picture.  
 
 
 
 
                                  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  . The scaffold functionalization with human fibronectin, conc. 1mg/ml (chemical composition).  
 
Figure  . The Human 
Fibronectin, courtesy of 
Prof Elspeth Garman – 
Dept. of Biochemistry, 
Oxford University (UK).  
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The characterization of Polyurethane (PU) scaffolds. The microstructural morphology of young 
and aged samples will be compared in terms of porosity, mean pore radius and mean pore 
roundness. By using a cryotome, PU slices with a thickness of 80μm were cut. Samples were 
embedded in a proper medium before cutting. Sections were obtained both from the top face (top 
section) of the scaffold and from the lateral face (transverse section). The results for 1 top section 
and 8 transversal sections will be presented for both a young and an aged sample. The height maps 
of each slice have been obtained by means of a laser scanning confocal microscope (LEXT-
OLS4100, Olympus) and a MATLAB script has been used for segmentation purposes. Specifically, 
a binary image has been obtained out of each height map, specifying a height threshold as a fraction 
of the maximum height value obtained in a slice. Height data were considered voids (white) if 
below the aforementioned threshold, while matrix (black) otherwise. Since the choice of the height 
threshold affects the segmentation results, the influence of this parameter will be discussed in the 
results session. Finally, a MATLAB script has been used to compute the following morphological 
quantities (porosity, roundness and mean pore radius) and the wall thickness (tw) was also measured 
by direct measurement on reflected intensity confocal images. Since this measurement was not 
automated by means of a script, while operated manually, only 1 slice out of the 8 slices available 
for transverse sections was considered for the measurement of an average value of the wall 
thickness of young and aged samples. Among the available slices, those showing sharper cuts were 
selected.  
 
 
 
 
 
 
The characterization results: on the influence of the segmentation threshold on the morphological 
quantities. In order to discuss the influence of the height threshold on segmentation results, the case 
of a top section of an aged sample will be presented in continue. When segmentation is pursued as 
described in the Methods section, the height threshold would have no influence on the final binary 
image in the ideal case featuring (i) a perfectly flat cutting plane and (ii) microstructural wall 
 
 
Figure  . The sketch of the orientation of cryotome cuts on the PU scaffold samples. Courtesy 
of Prof Pasquale Vena – Polytechnic School – University of Milan. 
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perfectly orthogonal with respect to the cutting plane. Indeed, the top surface of the slice is 
heterogeneous (Figure ), suggesting that the material was partially drawn by the blade during the 
cut. Furthermore, the walls of the microstructure are at an angle with respect to the cutting plane 
(Figure ). This might be either due to the overall orientation of the sample with respect to the blade 
or due to the inherent heterogeneous microstructural arrangement of the pores. The influence of the 
segmentation threshold was investigated comparing the values of the morphological quantities 
computed for threshold values (t) between 0 and 1, with 0.05 increment. Intuitively, one can 
imagine that increasing the segmentation threshold leads to thinner matrix walls (Figure ). 
 
 
 
 
 
           
 
 
 
 
 
 
 
 
 
 
 
Figure  . Height map of a top 
section of an aged sample. 
Courtesy of Prof Pasquale 
Vena – Polytechnic School – 
University of Milan. 
 
     
Figure  . Example of binary image of the same height map for different segmentation threshold choices. 
Courtesy of Prof Pasquale Vena – Polytechnic School – University of Milan. 
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A quantitative picture of the influence of the segmentation threshold is given by the following 
figures. The choice of the threshold highly affects the porosity. It was not possible to identify a 
range of segmentation values resulting in a constant value of computed porosity (Figure ). This 
reliability of the porosity values computed with this approach is then judged poor.  
A relatively stable value of roundness and mean pore radius was found for segmentation thresholds 
between 0.2 and 0.6 (Figure  and Figure , respectively). The roundness value range between 0.3 and 
0.4, meaning that most of the pores are far from being circular (i.e. c = 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  . Porosity values computed for the same slice segmented with different height thresholds. 
Courtesy of Prof Pasquale Vena – Polytechnic School – University of Milan. 
 
 
Figure  . Roundness values computed for the same slice segmented with different height thresholds. 
Courtesy of Prof Pasquale Vena – Polytechnic School – University of Milan. 
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A detail on the mean pore radius computed between t = 0.2 and t = 0.6 shows that R is in the range 
of 70μm. 
 
 
 
 
 
 
 
 
A similar behavior was found for the top section of a young sample (Figure ) and for the transverse 
sections of both aged and young samples (Figure  and Figure , respectively). When comparing 
curves of different slices belonging to the same sample, a further comment is suggested on the 
definition of the segmentation threshold: besides showing a similar trend, an offset seems to affect 
the results of some slices. Since the threshold is defined as a fraction of the maximum height of 
each height map, the same threshold value may correspond to different values in terms of absolute 
 
Figure  . Mean pore radius computed for the same slice segmented with different height thresholds. 
Courtesy of Prof Pasquale Vena – Polytechnic School – University of Milan. 
 
 
Figure  . Detail of the plateau value obtained for the mean pore radius. Courtesy of Prof Pasquale 
Vena – Polytechnic School – University of Milan. 
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height, depending on the specific slice which is queried. To investigate the influence of the 
segmentation threshold in terms of absolute height values would be a more proper choice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure  . Results of the morphological characterization on the top section of a fresh sample. The plots 
show the values of (a) porosity, (b) roundness and (c) mean pore radius computed for segmentation 
thresholds varying between 0 and 1. A detail on the region of relatively stable values of the mean pore 
radius is shown in the inset (d). Courtesy of Prof Pasquale Vena – Polytechnic School – University of 
Milan. 
 Figure  . Results of the morphological characterization on the 8 transverse sections of an aged 
sample. The plots show the values of (a) porosity, (b) roundness and (c) mean pore radius computed 
for segmentation thresholds varying between 0 and 1. A detail on the region of relatively stable 
values of the mean pore radius is shown in the inset (d). Courtesy of Prof Pasquale Vena – 
Polytechnic School – University of Milan. 
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Although the present segmentation method didn't show promising results in terms of reliability, a 
comparison between young and aged samples in terms of morphological parameters will be 
presented in the following paragraph. Based on previous comments, a segmentation threshold t = 
0.40 has been selected to compare different samples, this value falling within the range of 
segmentation parameters providing stable mean pore radius estimates for all the processed slices. 
The characterization results: on the comparison between young and aged samples. A qualitative 
comparison between representative height maps of fresh and aged samples is reported in Figure . 
 
 
 
 
 
 
Figure  . Results of the morphological characterization on the 8 transverse sections of a fresh sample. 
The plots show the values of (a) porosity, (b) roundness and (c) mean pore radius computed for 
segmentation thresholds varying between 0 and 1. A detail on the region of relatively stable values of 
the mean pore radius is shown in the inset (d). Courtesy of Prof Pasquale Vena – Polytechnic School – 
University of Milan. 
 
 
Figure  . Qualitative comparison 
between height maps of young 
(indicated as fresh) and aged samples.  
Courtesy of Prof Pasquale Vena – 
Polytechnic School – University of 
Milan. 
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In continue, a quantitative comparison of morphological quantities is presented. Since only 1 top 
slide was available for each sample type, the corresponding results were computed as defined in the 
Methods section. Since 8 transverse slides were available for each sample type, results for the 
transverse sections were further averaged among the results of each single slide. Thus, the standard 
deviation values are reported only in the case of transverse sections. As concerns porosity (Figure ), 
aged samples displayed lower porosity (-11.3%) as compared to young samples when comparing 
top sections, while the inverse trend (+11.8%) appeared when comparing the transverse sections. 
Nevertheless, when the standard deviation values are considered for the transverse section, no 
significant difference can be identified. Such a wide scattering of experimental results is assumed to 
be due to the current definition adopted for the segmentation threshold. As already mentioned, the 
same segmentation threshold corresponds, at the moment, to different absolute height values, which 
results in a horizontal shift of the curves describing the behavior of porosity vs segmentation 
threshold (see Figure  and Figure ). Switching to a definition of segmentation threshold to absolute 
height values is expected to improve results reliability and is recommended as a future task.  
 
 
 
 
 
 
 
Similar arguments apply for the roundness of pores (Figure ). Nevertheless, in this case it can be 
argued that, while the roundness of aged samples does not seem sensitive to the orientation of the 
cut, for young samples the pores display a slightly higher roundness in the transverse sections as 
compared to the top sections.   
 
 
 
Figure  . Quantitative comparison 
between the values of porosity 
computed for young (indicated as 
fresh) and aged samples, both in 
top and transverse sections. 
Courtesy of Prof Pasquale Vena – 
Polytechnic School – University 
of Milan. 
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The difference in terms of mean pore radius seems also sensitive to the orientation of the cut. Pores 
in young top sections were found to be bigger (80μm) as compared to young transverse sections and 
aged sections (Figure ). 
 
 
 
 
 
 
 
As concerns the wall thickness, measurements were performed on a sub-region of the original field 
of view of the corresponding slices, were a sharper cut was found and the cross-section of the 
matrix walls was more visible. For this reason, the pictures reported in Figure X are magnified as 
compared to previous views and the scale bar indicates the correct pixel proportion.  
The difference in terms of wall thickness values was more evident as compared to previous 
morphological quantities. The walls of aged samples were found to be 27,1% thinner as compared 
to young samples when top sections were considered. The same trend and a higher difference (-
43,5%) was found for transverse sections. The standard deviation is again significant, most likely 
due to a combination of material heterogeneity and operator uncertainty. 
 
 
Figure  . Quantitative 
comparison between the 
values of roundness computed 
for young (indicated as fresh) 
and aged samples, both in top 
and transverse sections. 
Courtesy of Prof Pasquale 
Vena – Polytechnic School – 
University of Milan. 
 
Figure  . Quantitative 
comparison between the values 
of mean pore radius computed 
for young (indicated as fresh) 
and aged samples, both in top 
and transverse sections. Courtesy 
of Prof Pasquale Vena – 
Polytechnic School – University 
of Milan. 
 
38 
 
 
 
 
 
 
 
 
 
 
 
 
 
As already mentioned, the cut is usually at an angle with respect to the scaffold walls, thus the use 
of the height profile to discriminate the thickness of the walls is rather unreliable. This is consistent 
with the reliability issues observed for the estimation of the porosity values: as long as only height 
maps data are concerned, measuring porosity or wall thickness can be practically considered 
complementary tasks, thus it is reasonable to meet similar issues. When considering reflected 
intensity images, the contrast between a cross section exposed by a sharp cut and the surrounding 
scaffold matrix is expected to be higher than in the case of height maps and profiles. For this 
reason, the wall thickness measurements were performed on reflected intensity images rather than 
height maps.  
Table 1 and Table 2, respectively summarize the quantitative comparison shown in previous plots, 
for both top and transverse sections.  
 
 
Figure X. Reflected intensity confocal images showing the regions were the wall thickness was manually 
evaluated, for both young (indicated as fresh) and aged samples. Courtesy of Prof Pasquale Vena – Polytechnic 
School – University of Milan. 
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Table 3.  Ingredients for scaffolds fabrication (young and aged samples).   
scaffold fabrication       PU       PCL      DMSO 
     
young                                     1,76g  0,00g       22ml 
aged 0,88g 0,88g       22ml 
       50%      50% 8% w/v 
Figure  . Quantitative comparison 
between the values of wall thickness 
computed for young (indicated as 
fresh) and aged samples, both in top 
and transverse sections. Courtesy of 
Prof Pasquale Vena – Polytechnic 
School – University of Milan. 
Table 1. Summary of quantitative comparison between morphological quantities of young (indicated as fresh) 
and aged samples. Values refer to the top sections. Courtesy of Prof Pasquale Vena – Polytechnic School – 
University of Milan. 
 
Table 2. Summary of quantitative comparison between morphological quantities of young (indicated as fresh) 
and aged samples. Values refer to the transverse sections. Courtesy of Prof Pasquale Vena – Polytechnic School 
– University of Milan. 
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Results and Discussion: polyurethanes were successfully synthesized as confirmed by Attenuated 
Total Reflectance Fourier Transform Infrared Spectroscopy and Size Exclusion Chromatography 
(Mn =70.000 g/mol). SEM results: scaffolds SEM micrographs show oriented fibers texture, like 
the cardiac muscle tissues topography. All the samples examined show a range of porosity between 
59 – 64% calculated by using the Image J software. The measured diameter of single pores is 
between 100,2mm – 152,6mm.  
XPS analysis results: XPS analysis of scaffolds confirmed the surface immobilization of ECM 
protein by changes in both chemical composition and C1s signal deconvolution. The O/C ratio is 
maximum for polyacrylic acid (PAA) grafted polyurethane (PUR), according to the presence of the 
PAA layer, rich in carboxyl group. The N/C ratio is higher in fibronectin immobilized surface, 
according to the presence of several amide groups. The protein treated surface shows also the 
highest percentage of C–N and C–O bond and a peak attributed to amide bond, according to the 
protein chemical composition.  
Water contact angle results: plasma activation led to a considerable reduction in the contact angle 
value; a decrease in wettability was observed after fibronectin immobilization.  
Mechanical tests results: polyurethane film is about 14MPa. Dynamic Mechanical Analysis (DMA) 
of scaffolds shows a storage modulus in the dry state of about 1MPa. The elastic modulus remains 
constant within a wide range of frequencies, indicating a good material pliability in different 
physiological or pathological states (stress-controlled DMA, Frequency Sweep conditions: f =1-100 
Hz; e = 1%; T = 37°C; Stress/Strain conditions: load cell = 18N, stress rate = 1N/min, T = 37°C). 
Biological test results: to evaluate the cell adhesion to the polyurethane scaffolds, primary neonatal 
rat cardiomyocytes were stained with an Acridine Orange. Then, cardiomyocytes were seeded on 
scaffolds and allowed to adhere for two days. From 4 days after cell seeding, constructs were 
analyzed using fluorescent microscopy. As shown in Figure X, primary cells colonized the scaffold 
surface and remained adherent to the scaffold for more than 50 days. To evaluate the cardiomyocyte 
self-beating activity, scaffolds were analyzed from 4 days after cell seeding every two days using 
fluorescent microscopy. Time lapse analysis demonstrated that cells beat synchronously from day 7 
and for over 50 days.  
Porous substrates showing anisotropic properties were successfully produced through TIPS under 
application of a cooling gradient. Further work will be necessary to study and evaluate the cell 
adhesion on an aged model of the same polyurethane scaffolds.  
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Figure . Scaffolds functionalization procedure.  
 
 
 
 
 
 
 
Figure  . SEM micrograph of the 
scaffold young and aged model.  The 
obtained polyurethane shows 
oriented fibers texture, like the 
cardiac muscle tissues topography. 
100g/ml 
 
Table 4. XPS analysis results.  
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Table 5. Water contact angle results.  
 
Figure . Histological analysis and Cell Titer Blue assay, 
courtesy of Prof Mara Brancaccio’s team – MBC Dept. 
University of Turin (Italy). 
 
Figure . Cardiomyocyte culture after 8, 15, 27,36 days; courtesy of Prof Mara Brancaccio’s team – MBC Dept. 
University of Turin (Italy). 
 
 
Figure . Actin cytoskeleton of myoblasts cultured 
for 7 days on the synthesized polyurethane (K-BC 
2000); courtesy of Prof Mara Brancaccio’s team – 
MBC Dept. University of Turin (Italy). 
 
 
Figure .  The SEM micrograph of my 
scaffold showing the pores size.  
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2.1.3.  CONCLUSION   
The MIND project started in 2010 and was fully financed by the Italian Ministry of Education for 5 
academic years. I joined the project during the academic year 2014 – 2015 and I had nice results. 
Working at this project gave me the chance to synthesize a new material, a new polyurethane with 
precise characteristics and the target to overcome the lack of laboratory models to study the heart 
ageing. After the kind invitation received from the Central European Institute of Technology 
(CEITEC) Brno – Czech Republic, the international conference committee selected my poster for a 
platform presentation in the category of Biomaterials. During the event “Frontiers in material and 
life sciences: Creating life in 3D” International Conference on 2-4 Sept 2015, hosted in Brno 
(Czech Republic) my talk has been awarded by the conference committee, the Executive director of 
CEITEC Dr Markus Dettenhofer and also by the international press and public.   
At present Myocardial Tissue Engineering and Regenerative Medicine represent a good strategy in 
order to revolutionize the treatment of cardiac diseases and the management of cardiac surgery. 
However, today there is the experimental evidence that following a good nutrition plan it will be 
possible to prevent common aging diseases. Prof Valter Longo – Longevity Institute, School of 
Gerontology, Department of Biological Sciences, University of Southern California (3715 
McClintock Avenue, Los Angeles, CA 90089, USA), in one of his fascinating manuscripts 
explained that immune system defects are at the center of aging and a range of diseases53. He 
continues giving the experimental evidence that prolonged fasting reduces circulating IGF-1 levels 
and PKA activity in various cell populations, leading to signal transduction changes in long-term 
hematopoietic stem cells (LT-HSCs) and niche cells that promote stress resistance, self-renewal, 
and line-age-balanced regeneration. Multiple cycles of fasting abated the immunosuppression and 
mortality caused by chemotherapy and reversed age-dependent myeloid-bias in mice, in agreement 
with preliminary data on the protection of lymphocytes from chemotoxicity in fasting patients. The 
pro-regenerative effects of fasting on stem cells were recapitulated by deficiencies in either IGF-1 
or PKA and blunted by exogenous IGF-1. These findings link the reduced levels of IGF-1 caused 
by fasting to PKA signaling and establish their crucial role in regulating hematopoietic stem cell 
protection, self-renewal, and regeneration52-56. At this point, in my opinion, it is widely clear that 
fasting inhibits IGF-1/PKA to promote stem-cell based regeneration in mice and humans. 
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2.2. A novel bactericidal surface to reduce nosocomial 
infections     
2.2.1. INTRODUCTION  
As antibiotic resistance continues to threaten the treatment of various infections, the aim of this 
work concerns the design of a new coating film containing light activated antimicrobial chemicals 
and nanoparticles to avoid microbes spread across hospitals. This work involves developing 
research areas that did not exist previously, such as the light activated polymers which have been 
studied at Chemistry Department UCL and in some cases commercialized58.  
It is well known that methicillin-resistant Staphylococcus aureus (MRSA) is a substantial public 
health problem not restricted to any geographic area, but worldwide. The same is true for the 
opportunistic pathogen Pseudomonas aeruginosa. Micro-organisms selected for this study were 
Epidemic MRSA 4742 representative of a Gram-positive epidemic bacteria isolated at UCL 
Hospital and Pseudomonas aeruginosa PAO1 as well as the clinical strand isolated at UCL Hospital 
representative of Gram-negative bacteria resistant to the majority of currently used antibiotics. 
Concerning this one a complementary study of its biofilm-mediated resistance to antibiotics has 
been followed supported by Prof E. Sapi (USA) and her team; [See Chapter 3 of this thesis].  
To satisfy the target the dye selected was crystal violet or gentian violet because it has been 
demonstrated that in vitro it can disrupt Pseudomonas aeruginosa biofilms and it can kill MRSA. 
The nanoparticles (NPs) used for this study were silver ions because the antimicrobial activity of 
Ag+ ions is well documented and reviewed. The antimicrobial polyurethane coating films produced 
were tested against these micro-organisms to demonstrate their efficacy59. It has been also studied 
the critical importance of the presence of silver nanoparticles to improve the functional property of 
the inanimate surface following Prof. N. Carlone (Italy), Prof. M. Vasil (USA) and Prof. E. Pohl 
(UK) suggestions. Antimicrobial activity of control and treated polyurethane samples on 4742 
MRSA and PAO1 after 5 hours of incubation at 500 lux has been examined. There is no MRSA 
growth with crystal violet (CV) solution and CV + Silver NPs solution in 5 hours. The situation 
changes in the case of PAO1 where the growth is reduced only by the solution containing silver 
NPs in 5 hours. However, after an incubation time of 24 hours in the dark a significant 
antimicrobial activity was observed. 
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Silver NPs used for this work remain inside of the polyurethane matrix – they stay into the bulk and 
not on the surface and exhibit potent antimicrobial activity. In addition to this, the combination of 
silver NPs and a light activated agent (CV) can provide a dual kill mechanism also under dark 
conditions. These surfaces are promising candidates for use in healthcare environments to reduce 
the incidence of hospital-acquired infections.  
 
2.2.2.  EXPERIMENTAL      
The Smart Surfaces project started at Chemistry Department University College London few years 
ago following the passionate research studies of Prof Michael Wilson – emeritus Professor of 
Microbiology at University College London. Among his main research interest there was the 
antibiotic resistance and the development of new antimicrobial strategies. He showed a great 
interest in translational research and has applied for 13 patents for inventions in the fields of light-
activated antimicrobial agents and water purification. The first article on Smart Surfaces entitled 
“Efficacy of a novel light-activated antimicrobial coating for disinfecting hospital surfaces” was 
published in November 2011 by Prof Michael Wilson, Prof Ivan P. Parkin, and their students60.  
It is well known that healthcare-associated infections are infections acquired from the result of a 
person’s treatment by health care providers and are caused by a variety of micro-organisms. These 
infections include: gastrointestinal infections (22%), urinary tract infections (20%), low respiratory 
tract infections (20%), surgical site infections (14%), skin and soft tissue infections (10%), 
bloodstream infections (7%) and others (7%). Unfortunately, every year there are at least 300 000 
incidents of healthcare-associated infections in hospitalized patients in England, costing the UK’s 
National Health Service (NHS) > 1 billion pounds a year. In recent years, significant effort has been 
devoted to preventing healthcare-associated infections attributed to methicillin resistant 
Staphylococcus aureus (MRSA), and Clostridium difficile because they have caused multiple 
fatalities60-65. The World Health Organisation (WHO) has published in 2017 a list of the 12 bacteria 
which pose the greatest threat to human health because they are resistant to antibiotics. 
Pseudomonas aeruginosa is the first one of the list of the three bacteria considered to be of critical 
priority. Methicillin-resistant Staphylococcus aureus is the second one in the list of the other six 
bacteria considered to be of high priority. If antibiotics lose their effectiveness, key medical 
procedures – including organ transplantation, caesarean sections, joint replacements, and 
chemotherapy – could become too dangerous to perform. The bacteria on WHO list can cause 
severe and often deadly infections such as bloodstream infections and pneumonia. The most critical 
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group of them includes multi-drug resistant bacteria that pose a particular threat in hospitals and 
nursing homes67. In the daily practice P. aeruginosa and S. aureus are the two most common causes 
of chronic wound infections and are frequently found together68. It has been experimentally 
demonstrated that exist synergistic interactions between P. aeruginosa and S. aureus in fact this one 
can produce lactate that is a carbon source that P. aeruginosa preferentially consumes over 
medium-supplied glucose69. In 2017 the Kazan Federal University (Volga Region, Russia), 
discovered that S. aureus survives in P. aeruginosa biofilm under antimicrobial treatment 
conditions70. In addition to this, the evidence suggests that P. aeruginosa – S. aureus infections are 
more virulent than monoculture infection with either species68. The big problem of Antibiotic 
Resistance will be fully described in Chapter 3 of this thesis.  
According to Hwang et al. 2016, contaminated surfaces in hospital serve as bacterial reservoir 
which can contribute to transmission of health care-associated pathogens via touch by patients and 
hospital workers59. Cleaning and disinfection of the surface have been used in hospitals to prevent 
surface contamination. Although cleaning may decrease the levels of surface contamination, it is 
difficult to eradicate entirely because firstly, the bacteria may be strongly adherent to the surface 
and even a small number of residual bacteria will quickly reproduce to significant numbers if 
environmental conditions are favourable. Secondly, it is not easy to implement the cleaning and 
disinfection schemes thoroughly. Thus, it is necessary to develop effective and applicable 
alternatives to inhibit pathogen transmission in hospitals71-77. 
 
 
 
 
 
 
 
 
 
Figure .  The WHO list of the 12 
superbugs published in February 2017.  
Source: 
www.who.int/mediacentre/news/releas
es/2017/bacteria-antibiotics-needed/en/  
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Materials and methods:  In order to prevent hospital surface contamination, at Chemistry Dept. 
UCL have been developed research areas that did not exist previously, such as the light activated 
polymers. To satisfy the target the dye selected was crystal violet or gentian violet because it has 
been demonstrated – by Wang et al. 2008, that in vitro it can disrupt Pseudomonas aeruginosa 
biofilms78 and it can kill MRSA80. The clinical utility of gentian violet was first demonstrated – by 
Saji 1992, in a series of patients with decubitus ulcers by using an ointment containing 0.1% 
gentian violet. In 12 cases of patients with the MRSA infected skin lesions, MRSA was eliminated 
completely from the infected areas of the skin within 4 weeks. The side effects of gentian violet 
were not observed in all cases during the use of the ointment containing gentian violet79-80. The 
efficacy of gentian violet has been also demonstrated – by Okano et al. 2000, while studying a 
broad range of MRSA skin and soft tissue infection and clearance of nasal carriage. In the 8 cases 
of impetigo, the mean time to eradication was 7 days and the in vitro minimum inhibitory 
concentration (MIC) of gentian violet was 0,0225g/mL. The dye agent was well tolerated in all 37 
patients, with no significant side effects being reported81. Synthesis of gentian violet was attributed 
French chemist Charles Lauth in 1861 under the name of “Violet de Paris” and was popularized by 
George Grubber, a German pharmacist in 1880. In 1912, Churchman noted the bacteriostatic action 
of gentian violet against Gram-positive bacteria both in vitro and in animal studies. Based upon 
results from Churchman, in 1925 Hinton used gentian violet intravenously in 12 patients with 
severe sepsis from Gram-positive bacteria, of which seven patients improved82. Separate studies by 
Bakker and Fung have found that gentian violet inhibited growth of Pseudomonas, an extremely 
virulent Gram-negative rod, in vitro. Gentian violet was found to be more active than brilliant green 
at pH 7.4, particularly against Pseudomonas aeruginosa. The spectrum of activity of gentian violet 
was not increased by the addition of brilliant green. An aqueous solution of gentian violet 0.5% 
turned out to be an adequate topical anti-infective drug83-84. Recently, a report by Wang et al. 2008 
showed that gentian violet disrupts and inhibits Pseudomonas aeruginosa biofilm in flow chambers 
and, also has some efficacy against planktonic Pseudomonas aeruginosa. The efficacy of gentian 
violet in vitro suggests that it may disrupt biofilm in vivo78. It is well known that many pathogens 
have developed systems that are controlled by the iron concentration to secret virulence factors, in 
Pseudomonas aeruginosa the ferric uptake regulator (Fur) is the protein that controls the iron 
uptake system and, consequently the expression of the virulence factor known as Exotoxin A85. Both 
excess iron and iron restriction have been implicated in reducing Pseudomonas aeruginosa 
biofilms78. More details about Pseudomonas aeruginosa and methicillin resistant Staphylococcus 
aureus (MRSA) will be given in Chapter 3 of this thesis.  
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The nanoparticles used for this study were silver ions because the antimicrobial activity of Ag+ ions 
is well documented and reviewed. Silver has been recognized for its antimicrobial properties for 
centuries. The Phoenicians used silver water vessels to keep water, wine, and vinegar pure during 
their long voyages. Hippocrates, the "Father of Medicine", wrote that silver has healing and anti-
disease properties. Greeks, Romans, and Egyptians used silver to purify and preserve water86. In 
North America, pioneers put silver dollars coins in their water flasks and barrels before journeying 
west. At the beginning of the twentieth century (1900-1940) surgeons routinely used silver sutures 
to reduce the risk of infection and promote healing87. Silver, a naturally occurring element, is non-
toxic, hypoallergenic, does not accumulate in the body to cause harm and is considered safe for the 
environment. After testing 23 methods of purifying water, NASA has also chosen silver as the 
purifying agent on the Space Shuttle program. Positively charged silver particles literally seek out, 
oxidize, and destroy negatively charged bacteria and, in general all pathogens. In fact, silver is anti-
bacterial, anti-microbial, anti-viral, and anti-fungal88.  
A series of samples were prepared for microbiological testing using a novel two-step dipping 
method. A simple swell-encapsulation-shrink process was employed to incorporate crystal violet 
(CV) dye and silver nanoparticles (Ag NPs) into polyurethane using acetone as a swelling solution. 
In the swell-encapsulation process, the CV molecules and Ag NPs in the acetone penetrate the 
polyurethane matrix as it swells, and the polyurethane then shrinks when it is removed from the 
solution. The CV molecules and Ag NPs remain inside of the polyurethane matrix.  
Preparation of chemical stock solutions. The crystal violet solution – solution A was prepared 
dissolving 60mg of crystal violet powder (CV, Sigma-Aldrich, St. Louis, MO, USA) in 100ml of a 
solution containing 10ml of DI water and 90ml of acetone. The solution was sonicated in an 
ultrasound bath for 5 min in order to ensure complete dissolution of CV powder. The solution B 
was prepared dissolving 45mg (0.26mM) of AgNO3 (Silver nitrate, Sigma-Aldrich, St. Louis, MO, 
USA) in 50ml of DI water to produce an approximately 5mM solution. The solution C was prepared 
dissolving 294.7mg (1mM) of Na3C6H5O7∙2H2O (tri-sodium citrate dihydrate, Hopkin & Williams 
Ltd, London, UK) in 50ml of DI water to form a 20mM solution. Synthesis of silver nanoparticles 
was prepared mixing 10ml of solution B with 180ml of DI water and heated with constant stir. 
After the mixture was boiled for ⁓ 2 min, 10ml of solution C was added. With constant stir, the 
mixture was boiled for a further 30 min and then allowed to cool. The development of a yellow 
colour was observed during the process.  
Preparation of white light-activated antimicrobial surface. Polyurethane squared samples 
(1.0×1.0cm) were immersed in 10ml of acetone solution and left to swell in the dark for 24 h and 
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then left to dry in the air. Polyurethane dried samples were immersed in solution A (CV solution) 
and left to swell in the dark for 24 h. The samples were recovered from the CV solution and washed 
using a DI water bath sonicator for 2 times and then air-dried for 24 h in the dark. The samples were 
prepared as follows: CV only, CV with Ag NPs. Additionally, NPs encapsulated polyurethane 
samples without CV were prepared as follows: polyurethane with Ag NPs.  
Material characterization. TEM (JEM-2100, JEOL Inc., Peabody, MA, USA) with EDS was used 
to confirm the size, morphology, and chemical composition of synthesized NPs. (Figure 0)  
The UV-vis absorption spectra against NPs suspensions, control and treated samples were measured 
using UV-vis Spectrometer (PerkinElmer Inc., Winter St., CT, USA). Absorption was measured 
from 350 to 900nm. To determine NPs uptake from NPs suspension to polyurethane, the UV-vis 
spectra of NPs suspension were measured before and after swell-encapsulation-shrink process. The 
polymer sample was immersed in a mixture of acetone (9ml) and NPs (1ml) for 24 h. The 
comparison of absorbances before and after at 409nm (Ag NPs) was enable determination of the 
amount of silver NPs absorbed in the polymer. The uptake rate of NPs from NPs suspension to 
polyurethane sample was calculated as follow;  
Uptake rate (%) = 100 × ቆ 
(AUୠୣ୤୭୰ୣ −  AUୟ୤୲ୣ୰)
AUୠୣ୤୭୰ୣ
 ቇ   
where AUbefore represents the absorbance of NP suspension before polyurethane immersion in the 
solution and AUafter shows the absorbance of NPs suspension after the polymer removal.   
Wetting properties. Equilibrium water contact angle measurements on: untreated polyurethane, 
acetone treated polyurethane (control), crystal violet-coated polyurethane, crystal violet-coated 
nano-silver encapsulated polyurethane, and nano-silver encapsulated polyurethane, were also 
obtained. A droplet of deionised water was dispensed by gravity from a gauge 27 needle and the 
samples were photographed side on. The data were analysed using Surftens 4.5 software.   
 
  
   
 
Table 6. Average water contact angle measurements (°) ± standard deviation, 
of water on a range of polyurethane samples.      
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Antimicrobial tests. To examine the antimicrobial activity, a range of polyurethane samples 
(1.0×1.0cm) was used to perform the experiments: acetone treated polyurethane (control), crystal 
violet-coated polyurethane, crystal violet-coated nano-silver encapsulated polyurethane, and nano-
silver encapsulated polyurethane. These samples were tested against Epidemic MRSA 4742 
representative of a Gram-positive epidemic bacteria isolated at UCL Hospital and Pseudomonas 
aeruginosa PAO1 as well as the clinical strand isolated at UCL representative of Gram-negative 
bacteria resistant to the majority of currently used antibiotics. These organisms were stored at – 
70°C in Brain-Heart Infusion broth (Oxoid Ltd, Hampshire, England, UK) containing 20% (v/v) 
glycerol and propagated on Columbia Agar Base (Lab M Ltd, Lancashire, England, UK) + 5% 
defibrinated horse blood (E&O Laboratories Ltd, Bonnybridge, Scotland, UK).  
BHI broth (10ml) was inoculated with one bacterial colony and cultured in air at 37°C for an 
incubation of 18 h with shaking, at 200 rpm. The bacterial pellet was recovered by centrifugation 
(21°C, 2000×g, 5 min), washed in phosphate buffered saline (PBS) and centrifuged again to recover 
the bacteria, which were finally re-suspended in PBS (10ml). The 2 times washed suspension was 
diluted 1000-fold in PBS to obtain the inoculum. The inoculum contained 4.6×106 colony forming 
units per mL (CFU mL-1). The inoculum in each experiment was confirmed by plating ten-fold 
serial dilutions on agar for viable counts. Duplicates of each polymer sample type were inoculated 
with 25L of the inoculum (containing 1.1×105 CFU) and covered with a sterile cover slip 
(22mm×22mm) to ensure good contact between the bacteria and the sample surface. The samples 
were placed into plastic petri dishes containing moistened filter paper to maintain humidity at room 
temperature. The samples were then irradiated for up to ⁓5 hours using a white light source, the 
white light intensity was measured using a lux meter (LX-101, Lutron Inc., Coopersburg, PA, USA) 
at a distance of 30cm from the light source. The intensity of the light ranged from 390 to 530 lux. A 
further set of samples (in duplicate) was maintained in the dark for the duration of the irradiation 
time. In the dark, the light was completely blocked (0 lux). After light exposure, the inoculated 
samples and cover slips were placed into 450l of PBS, and mixed using a vortex mixer for 1 min. 
The neat suspension and ten-fold serial dilutions were plated on Columbia blood agar for viable 
counts. The plates were incubated aerobically at 37°C for 24 h. Finally, the colonies grown on these 
plates were counted. All experiments were reproduced three times for each bacterial type.    
Results and discussion: In this work it has been used a simple “two-step” method to develop a 
polymer encapsulated with a phosensitiser dye in addition to silver nanoparticles.  In the first step, 
the polyurethane samples were immersed in an acetone swelling solution. In the subsequent step, 
the same samples were immersed half in a crystal violet solution for 24 h and the other half in a 9:1 
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crystal violet solution : nano-silver solution for 24 h. Upon exposure to the solvent, the polymer 
swells enabling the dye molecules to diffuse through the polymer. Although the mechanistic details 
are not so clear, it is clear that the CV dye strongly attaches to the polymer surface under aqueous 
dipping conditions, as the polymer sections showed no detectable leaching of crystal violet.   
 
 
 
 
 
 
 
 
The NPs were made by citrate reduction of boiling aqueous solution of AgNO3. The mean size of 
Ag NPs was 22.4 ± 16.7nm with median of 22nm, and interquartile range (IQR) of 24nm. They 
showed at TEM a spherical morphology as shown in figure 0. EDS analysis confirmed that all of 
peaks were assigned to Ag and impurities were not detected. Transmission electron microscopy 
(TEM) and energy-dispersive X-ray spectroscopy (EDS) were used in order to characterize the NPs.    
 
  
 
 
 
 
 
 
Figure .  The simple “two-step” dipping method: the bactericidal surface was prepared by incorporating 
crystal violet and silver nanoparticles into the polyurethane using a simple dipping technique. 
 
       
Figure 0. TEM photos selection of my silver nanoparticles. These photos have been taken under the kind 
guidance of Dr Steven Firth – Chemistry Dept. UCL.  
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The UV-vis absorption spectra of the Ag NPs suspension exhibited a peak at 409nm. Absorption 
was measured from 350 to 900nm. To determine the total amount of NPs encapsulated inside the 
polyurethane samples, the UV-vis absorbance spectra of nanoparticles suspension were measured 
before and after swell-encapsulation-shrink process. The polyurethane sample was immersed in a 
mixture of acetone (9mL) and NPs (1mL) for 24 h. Only the 8% of Ag NPs in the suspension was 
absorbed to polyurethane sample. The Ag NPs uptake rate from the NPs suspension to polyurethane 
sample was 8 ± 0.5% (average water contact angle ± standard deviation).     
 
 
 
 
 
 
 
To examine modified polyurethane functional properties, some samples of it were wiped rigorously 
with 70% alcohol. There was no visual evidence of dye removal from the treated polymer surface 
under these cleaning conditions, indicating the modified polymers should be stable with respect to 
standard hospital cleaning protocol. This test is considered a very important one, since despite the 
potent antimicrobial nature of these polymers, it is anticipated that surfaces treated by this method 
may still undergo the regimented hospital cleaning protocol and thus, must be stable to robust 
wiping using an alcohol-based, anti-infective wipe.  
 
 
 
 
 
                   
Figure !. The UV-vis absorbance spectra of the Ag NPs suspension before and after swell-encapsulation-
shrink process respectively. Comparison of absorbances before and after at 409nm of Ag NPs.  
Table 7. Recommended light intensities for different 
areas in the UK healthcare environments. 
Environment Light 
intensity/lux 
Operating theatre                                     10 000-100 000 
A&E examination room  
 
   1000 
Ward corridors 
 
   ≥200 
Typical dental chair    250 
Measurement performed  
at UCLH (NHS)  
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The lighting condition used in this study can be considered in relation to the brightness of various 
areas in the UK healthcare environments, as recommended by the Department of Health (Table 7)89 
and it was found that they were similar to those typically found in hospital corridors and wards; 
areas in which microbial contamination is prevalent. It is anticipated that the dye degradation is 
correlated to the light-flux levels and thus, the samples tested indicate a strong stability and 
suitability for these antimicrobial surfaces to be employed in a clinical environment such as hospital 
wards, where they would be expected to maintain the full potency for about 2 years (based on light-
flux level used).  
The antimicrobial activity of the control, CV dyed polyurethane samples, CV dyed and nano-silver 
encapsulated polyurethane samples and nano-silver encapsulated polyurethane samples under white 
light and dark conditions was tested against a representative strain of the Gram-positive bacterium, 
MRSA and, against a representative strain of the Gram-negative bacterium Pseudomonas 
aeruginosa. The data show that the antimicrobial activity of the polymers was promoted by 
exposure of the samples to a white hospital light source; a compact fluorescent lamp which emits 
light across the visible region of the spectrum and is similar to those commonly found in the UK 
NHS hospitals. In all experiments, a control sample set was maintained under dark conditions for 
the same period of time as the samples exposed to light and in a further experiment, a sample set 
was incubated under dark conditions for an extended time period (24 h). The antimicrobial activity 
of crystal violet-coated polyurethane (CV only), crystal violet-coated nano-silver encapsulated 
polyurethane (CV Ag) and nano-silver encapsulated polyurethane (Ag only) was compared to that 
of a control, solvent treated polyurethane sample. The lethal photosensitization induced by these 
samples when exposed to a white light source emitting an average light intensity of ⁓500 lux at a 
distance of 30 cm from the samples for ⁓5 h is shown in Figure .   
 
 
     
 
 
 
 
 
Figure !. Antimicrobial activity of 
control and treated polyurethane 
(PU) samples on 4742 methicillin-
resistant S. aureus at 500 lux for 5 
hours of incubation.  
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After 5 h at 500 lux, no reduction in the numbers of viable bacteria of MRSA 4742 was observed on 
the surfaces of the control material (polyurethane alone) and the nano-silver encapsulated 
polyurethane (Ag only). However, a statistically significant (P-value < 0.01) decrease in the number 
of viable bacteria was observed on the material containing crystal violet alone (2.08 log reduction in 
bacterial numbers) and crystal violet with Ag NPs (2.08 log reduction). After 5 h in dark conditions 
no significant reduction has been found in all samples, however after 24 h in the dark polyurethane 
containing CV alone and CV with Ag NPs showed a significant reduction in the numbers of 
bacteria below the limit of detection (P-value < 0.01, detection limit: below 102 CFU mL-1). 
Additionally, in experiments of polyurethane containing Ag NPs only, no reduction in the number 
of viable bacteria was confirmed after 5 h incubation in the dark. However, after 24 h in dark 
condition, a significant reduction was observed on polyurethane with Ag NPs only (P-value < 0.01, 
detection limit: below 102 CFU mL-1).  
Concerning the antimicrobial activity of the polyurethane samples against the Gram-negative 
bacterium P. aeruginosa, at the same light and dark conditions used for the MRSA, the following 
data has been found as shown in Figure .  
 
 
 
 
 
 
 
 
 
After 5 h at 500 lux, no reduction in the numbers of viable bacteria of PAO1 was observed on the 
surfaces of the control material (polyurethane alone), polyurethane with only CV and polyurethane 
containing CV and Ag NPs. However, a statistically significant (P-value < 0.01) decrease in the 
number of viable bacteria was observed on the material containing Ag NPs alone (0.89 Log 
reduction). After 5 h in dark conditions no significant reduction has been found in all samples, 
 
0
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light conditions - 500 lux 5 hours
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Figure !. Antimicrobial activity of 
control and treated polyurethane (PU) 
samples on PAO1 Pseudomonas 
aeruginosa at 500 lux for 5 hours of 
incubation.  
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however after 24 h in the dark polyurethane containing only Ag NPs showed a significant reduction 
in the numbers of bacteria below the limit of detection (P-value < 0.01, detection limit: below 102 
CFU mL-1). Additionally, in experiments of polyurethane containing only CV and CV with Ag 
NPs, no reduction in the number of viable bacteria was confirmed after 5 h and 24 h of incubation 
in dark conditions. An identical situation has been found performing the same experiments for the 
clinical strand isolated at UCL Hospital of the bacterium Pseudomonas aeruginosa.  
The XPS analysis of these samples – acetone treated polyurethane (control), crystal violet-coated 
nano-silver encapsulated polyurethane, and nano-silver encapsulated polyurethane, confirmed that 
silver NPs remain inside of the polyurethane matrix, consequently nothing has been found on the 
samples surface.   
 
 
 
 
 
 
 
 
 
The photo-bactericidal activity of polyurethane samples can be explained as follows; under white 
light condition, CV molecules in polyurethane are excited to a high energy triplet state from a low 
ground state. The triplet state dye reacts via type I (biomolecular reaction) or/and type II (reaction 
of molecular oxygen) photochemical pathways to produce ROS and 1O2 leading to bacterial death. 
It was speculated that NPs incorporation enhances type I or type II photochemical reaction of the 
dye molecules90. To determine enhancement of 1O2 generation, measurement of singlet oxygen was 
conducted at UCL Chemistry Dept. Laboratories. It has been estimated that the reactive oxygen 
species, singlet oxygen, has a very short diffusion distance of around 0.2 microns within the 
polymer91. Only dye embedded near the polymer surface will act in the photosensitisation of 
bacteria, as only the reactive oxygen species generated near to the polymer surface, rather than that 
   A           B  
  C  
Figure . XPS analysis results of polyurethane 
samples: A control, B crystal violet with silver 
nanoparticles and C silver nanoparticles alone. 
These XPS analysis have been made under the 
kind guidance of Dr Michael Powell – 
Chemistry Dept. UCL.  
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generated within the bulk, will act to photo-damage bacteria. With high concentrations of 
photosensitiser on the crystal violet-coated polymer surfaces, there is a greater probability of the 
generation of cytotoxic reactive oxygen species within range of “attack” against bacteria colonising 
the surface, subsequently contributing to the increased bacterial kills. These samples demonstrate 
efficacious antimicrobial activity when tested against both Gram-positive and Gram-negative 
bacteria, commonly associated with nosocomial infections. It is anticipated that these bactericidal 
surfaces can be employed in hospitals for use in touch surfaces, including but not limited to: tablet 
and mobile phone covers and screen protectors92, computer keyboards, hand-dryers and paint films, 
to help maintain low bacterial levels and hence, potentially reduce the risk of spreading infections. 
In addition, this technology has been recently applied at UCL Hospitals for use in medical devices 
such as catheters58-59.  It is expected that Ag incorporated polymers could be used to develop 
antimicrobial surfaces for clinical environments and also for various appliances such as keyboards, 
mobile phones and tablet covers, and also toilet and kitchen surfaces. However, for a real and daily 
application of the polymer, adverse effects on human health should be considered.  As Ag NPs used 
in this study have been widely used in food industry, medicine, and water quality control, studies of 
their toxicity have been extensively conducted93-99. The toxicity of Ag NPs depends on many 
factors including size, dosage, and exposure time. Tests against mammals conducted in vivo 
demonstrated that Ag NPs only had toxic effects at long term (28-90 days) and high concentration 
dosages (inhalation: >104 particles per cm3, ingestion: >30 mg kg-1)100-101.    
 
 
 
 
 
 
 
 
 
 
Figure . The photo-bactericidal activity of polyurethane samples: under white light condition, CV 
molecules in polyurethane are excited and so, ROS and 1O2 are produced, leading to bacterial death. 
Courtesy of Dr S. Noimark and Dr K. Page – Chemistry Dept. UCL.  
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2.2.3.  CONCLUSION   
For the first time at Chemistry Dept. UCL have been developed Smart Surfaces made of a potent 
light-activated antimicrobial polyurethane – using polymers incorporated with multi-dye-
nanoparticles combinations, that also demonstrated an effective killing power under dark 
conditions. It has been enough to use a standard hospital white light source to activate the 
photobactericidal power of the crystal violet-coated polymers. The samples were obtained 
following a simple swell-encapsulation-shrink process, crystal violet alone and in combination with 
silver nanoparticles was incorporated inside a polyurethane used in healthcare applications. This 
incorporation resulted in a potent white light-activated antimicrobial surface that demonstrated also 
a good bactericidal activity under dark conditions (24 h), reducing bacterial viability and, 
consequently bacterial number, below the detection limit. The multi-mechanism antimicrobial 
activity proves attractive in terms of potential applications for use in a variety of hospital surfaces, 
as low bacterial levels will be maintained under non-optimal lighting conditions (i.e. at night, or 
when lights are dimmed), with a boost in antimicrobial activity achieved with increasing 
illumination intensity. It is anticipated that these smart surfaces because of the fact that silver 
nanoparticles remain inside of the polyurethane matrix, exhibited a potent antimicrobial activity and 
in combination with a light-activated agent – crystal violet, are promising candidates for being used 
in healthcare applications, healthcare environments to reduce the surface bacterial contamination 
and thus, the incidence of hospital-acquired infections.  In particular concerning my samples, the 
final target will be to develop a bactericidal surface able to kill at the same time both methicillin-
resistant Staphylococcus aureus and Pseudomonas aeruginosa for using it in healthcare 
environments to reduce the spreading of nosocomial infections (i.e. hospital floors are heavily 
contaminated102).  The possible applications of my polyurethanes are shown in the picture below.   
         
 
 
 
 
 
  
Figure . The possible applications of my antimicrobial polyurethanes: screen protectors and 
keyboards for ultrasound full console machines, aerosol therapy devices and hospital shoes.  
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In the academic year 2017 the UCL Smart Surfaces project has been really appreciated by the 
public and the press (The Times) and the other media (BBC radio and TV and, RAI London TV). In 
particular, this project has been selected to represent the innovation in the field of chemistry103 
during the prestigious event managed by the Royal Society of London on 4th – 9th July 2017 entitled 
“The Royal Society SUMMER SCIENCE EXHIBITION 2017”. The UCL Smart Surfaces exhibition 
stand was the n°20 at The Royal Society 6-9 Carlton House Terrace, London SW1Y 5AG. It has 
been described as follows: “Touch the new self-cleaning materials, based on lily pads, that can kill 
bacteria and prevent infection”. In conclusion, I can confirm that the UCL Smart Surfaces project 
and my work on it, has been very appreciated across the world (U.S.A., Australia, New Zealand, 
Singapore, UAE, and Europe).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure . The UCL Smart Surfaces 
Exhibition stand ready on the day 
before the beginning of the event 
(Sunday 3rd July 2017). Courtesy 
of Dr S. Noimark and Dr K. Page – 
Chemistry Dept. UCL. 
 
Figure . The Sunday Times article about UCL Smart Surfaces (2nd July 2017, 12:01 am). 
Courtesy of Dr S. Noimark and Dr K. Page – Chemistry Dept. UCL. 
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Figure . The Press (E), the radio (B), and the television (A, C, D) at the Royal Society Summer Science 
Exhibition 2017 – London, UK. Courtesy of Dr S. Noimark and Dr K. Page – Chemistry Dept. UCL. 
 
 
 
 
A 
B 
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Figure . The Smart Surfaces prototypes (A): antimicrobial 
keyboard, mouse, smartphone cover and the antimicrobial 
catheters. The teaching station with microscope (B). Courtesy 
of Dr S. Noimark and Dr K. Page – Chemistry Dept. UCL. 
 
 
A B 
Figure . The long queue of people coming at the Royal Society Summer Science Exhibition 
2017 – London, UK. Courtesy of Dr S. Noimark and Dr K. Page – Chemistry Dept. UCL. 
             
 
      
Figure . My own teaching 
moments at the Royal 
Society Summer Science 
Exhibition 2017 – London, 
England, UK.  
In particular, in this small 
selection of personal 
photos, I was explaining to 
kids, high school students 
and adults the chemistry of 
UCL Smart Surfaces and 
their antimicrobial power 
and, of course the benefits 
for the human health.  
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Figure . Her Majesty The Queen of 
the United Kingdom and the other 
Commonwealth Realms Elizabeth II 
during her visit at UCL Francis Crick 
Institute on 9th November 2016. 
Courtesy of the University College 
London. 
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Chapter 3 
New Materials and Strategies to 
overcome the upcoming problem of 
antibiotic resistance  
 
 
3.1 Silver nanoparticles to improve control of 
nosocomial infections  
3.1.1. INTRODUCTION  
The rise of the Superbugs and the Antibiotic Resistance is the big problem of our time, in fact the 
WHO has come up with a list of antibiotic-resistant “priority pathogens” – 12 families of bacteria 
that pose the greatest threat to human health. The WHO said the 12 bacteria have built-in abilities to 
find new ways to resist treatment and can pass along genetic material that allows other bacteria to 
become drug-resistant as well. “Antibiotic resistance is growing, and we are fast running out of 
treatment options. If we leave it to market forces alone, the new antibiotics we most urgently need 
are not going to be developed in time” said Dr Marie-Paule Kieny, WHO’s assistant director-
general for health systems and innovation114. In order to give a comprehensive tractation of the 
problem I fully reported the Reuters article written by Yasmeen Abutaleb, Ryan McNeill and 
Deborah J. Nelson on 18th November 2016 entitled “One life, two donated organs and $5.7 million 
in bills – a tale of superbugs’ deadly costs”.  The deadly epidemic America is ignoring – The 
Uncounted, a Reuters Investigation115.   
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Recovering from transplant surgery, Dan Greulich fell prey to a drug-resistant infection. What 
happened over the next five months shows the terrible human and financial price of an epidemic 
raging through the U.S. healthcare system.  
LOS ANGELES – With good reason, Dan Greulich’s doctors called him “the miracle man.” In the 
span of a decade, the insurance company executive engaged not once, but twice, in a race with 
death as he awaited replacements for failing organs. And twice, just as death was poised to win, he 
made it to the top of the national transplant list – ahead of thousands of other dying people. Donor 
organs became available, he was rushed into surgery, and he emerged with a new lease on life. 
After Greulich’s second combined liver-and-kidney transplant in early 2012, his wife, Rae, sent a 
letter to the donor’s family. “You not only saved a man,” she wrote, “you saved a family.” But then, 
less than three weeks into his recovery at University of California-Los Angeles Medical Center, 
Greulich contracted an antibiotic-resistant infection – a common and often lethal hazard of hospital 
stays. Over the next five months, according to thousands of pages of medical and billing records 
reviewed by Reuters, Greulich was attacked by no fewer than half a dozen different “superbugs,” 
most of them strains that are encountered almost exclusively in healthcare facilities. Greulich’s 
immune system, suppressed by medications to prevent organ rejection, had no way to fight the 
bacteria. When the usual antibiotics failed to snuff them, he was pumped full of powerful 
alternatives, sometimes as many as half a dozen a day. Some had alarming side effects — hearing 
loss, severe pain, nausea. The infections kept coming. Sepsis, a dangerous inflammatory response to 
infection, set in. Confined to an intensive-care unit (ICU), Greulich was frequently placed on 
mechanical ventilation, itself a common source of infection. He wavered in and out of 
consciousness. Doctors cut him open again to seek the source of the problem. At one point, they 
considered putting him back on the transplant list, but only if they could clear him of infection. 
They couldn’t. On June 30, 2012, Greulich died, age 64. Dan Greulich is one of the uncounted – the 
tens of thousands of people in the United States whose infections and deaths by superbug are not 
tracked by public health agencies. As revealed in the first article in this series, deaths related to 
drug-resistant infections often aren’t recorded as such on death certificates. Greulich’s death 
certificate blames “cardiac arrhythmia,” or an irregular heartbeat. Even when superbug deaths are 
recorded, tens of thousands a year go uncounted because federal and state agencies are doing a poor 
job of tracking them. Today, the lack of a unified national surveillance system makes it hard to fight 
a scourge that officials 15 years ago declared to be a grave threat to public health. Deaths like 
Greulich’s speak to the high human toll of superbugs. But Greulich’s death and, in particular, the 
effort to prevent it also speak to the enormous waste caused by the infections: two precious organs 
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in a country where 22 people die every day waiting for one; thousands of hours put in by dozens of 
doctors, nurses and other medical workers to save a life; and big sums of money spent on drugs, 
surgery and hospital care, contributing to the billions of dollars superbugs add to the U.S. healthcare 
bill every year. “Two people that could have gotten those organs died waiting for those organs,” 
Rae Greulich said. “To see it become a failure is certainly devastating,” said Dr David Klassen, 
chief medical officer of the United Network for Organ Sharing (UNOS), the Richmond, Virginia, 
nonprofit group that coordinates all U.S. transplants. It isn’t clear how Greulich contracted the 
superbugs that killed him. UCLA Medical Center declined to make anyone available to discuss his 
illness and hospitalization. In a statement emailed to Reuters, the hospital said: “We treat many 
severely ill patients who require complex care, and we have detailed procedures and protocols in 
place to prevent, detect and treat infections.” Beyond the loss of viable organs that could have saved 
other lives, Greulich’s infections added to the growing national tab for treating them. Records show 
that from the time he first entered UCLA Medical Center in December 2011, until he died seven 
months later, Dan Greulich racked up a total bill of $5.7 million. How much of that went toward 
treating Greulich’s superbug infections and how much went toward his transplant surgery and 
related treatments is hard to determine precisely. Too many other variables are at play. However, at 
$5.7 million, the charges for Greulich’s seven-month hospitalization were nearly five times what 
the National Foundation for Transplants says are the average first-year charges for a liver-and-
kidney transplant. Charges for antibiotics he was given in a failed attempt to beat his infections 
were at least $230,000, exceeding the $200,000 in charges for obtaining and transplanting a liver 
and kidney. Charges for seven months of “accommodations” at UCLA Medical Center totaled $2 
million.  
AN ELUSIVE NUMBER. Lack of reliable data hinders any effort to calculate how much superbugs 
add to overall U.S. healthcare costs. The Centers for Disease Control and Prevention (CDC) cites 
figures from a 2009 study sponsored by the Alliance for Prudent Use of Antibiotics that put the 
annual cost of antibiotic-resistant infections at more than $20 billion. But that figure is extrapolated 
from data from a single hospital. And it uses infection rates from 2000, which were far less than 
what they are now. Dr Stuart Levy, director of Tufts University’s Center for Adaptation Genetics 
and Drug Resistance in Boston and an author of the 2009 study, acknowledged the limitations of the 
analysis. “The important point was we were supposed to show this was a very costly consequence 
of doing hospital care,” he said. Reuters undertook its own analysis to get an idea of how much 
superbug infections cost. Using national inpatient data from the federal Agency for Healthcare 
Research and Quality for 2013, the analysis of millions of records focused on infections from two 
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superbugs: methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile. It found 
that an infection can add thousands of dollars to the cost of a patient’s hospital stay. The average 
MRSA infection added about $11,000 per inpatient stay, while C. difficile added about $5,200. In 
all, Reuters found that the two infections combined added about $6 billion in charges to hospital 
stays nationwide in 2013. MRSA infections added about $4.1 billion, and C. difficile added about 
$1.9 billion. To calculate those numbers, Reuters used a method called propensity score matching to 
compare costs for patients with and without infection who are otherwise similar in terms of 
demographic characteristics, other illnesses, hospital setting and so on.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure . The analysis of Dan Greulich’s medical billing records – the Uncounted, a Reuters Investigation115.  
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While MRSA and C. difficile are two of the most common and well-known drug-resistant 
pathogens, they are only two of 18 superbugs the CDC considers to be a threat to public health, 
suggesting a total cost much higher than $6 billion. Some of those other infections, while not as 
widespread, can be far more costly to treat. Most superbug infections are contracted in hospitals and 
other medical facilities. The big bills that result are most often covered by health insurers and other 
third-party payers. This means that ultimately, the costs are passed to consumers in the form of 
higher insurance premiums, said David Cutler, a Harvard University economist who specializes in 
healthcare. “There is no other way to do it,” he said. Private insurers generally do not deny 
reimbursement for treatment related to superbug infections. Even in cases where hospitals are held 
legally liable for the infections, they are often shielded from eating the full cost. James Woodard 
contracted a MRSA infection at age 64 while in the University of New Mexico Hospital for back 
surgery in 2012. The infection led to a dozen more surgeries over four years and left him 
wheelchair-bound and with memory loss. But he hasn’t forgotten the pain as the infection spread: 
“It felt like someone was hacking my body in half,” he said. In a malpractice suit Woodard and his 
wife brought against the hospital, a jury earlier this year found the hospital at fault and awarded 
Woodard and his wife $4.25 million for medical costs, Woodard’s injuries and other damages. But 
New Mexico caps malpractice awards. Within those limits, the hospital is asking the court to set the 
award at $700,000, said hospital spokesman Luke Frank. That is less than the $973,000 that Frank 
said the hospital received in payments from Woodard’s insurer. Hospitals “make money on those 
complications,” said Woodard’s lawyer, Amalia S. Lucero. And Woodard could end up with even 
less if his own insurer recovers some of the money it paid to the hospital from whatever award 
Woodard receives. More than half the states have imposed caps on malpractice awards in response 
to medical and insurance industry concerns that multi-million-dollar verdicts were driving up the 
cost of healthcare and premiums. The Centers for Medicare & Medicaid Services (CMS) penalizes 
hospitals for high infection rates by reducing payments from the huge Medicare government health-
insurance program for the elderly. And the agency does not pay the added costs of some types of 
preventable infections, such as catheter-associated urinary tract infections, if they are contracted in 
the hospital. Hospitals have found a way to get around the CMS payment restrictions. Several 
studies have shown that hospitals sometimes use a strategy called “upcoding,” whereby they 
manipulate the codes for submitting reimbursement claims so that they receive payment for 
infection-related treatments. For instance, a hospital could claim an infection was present when the 
patient was admitted, rather than acquired in the hospital. Or it could not mention an infection at all.  
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A 2015 study from the Stanford Graduate School of Business estimated that CMS reimbursed for 
more than 10,000 “upcoded” claims from 2009 to 2010, costing Medicare a total of $200 million. 
As for Dan Greulich’s $5.7 million bill, his widow, Rae, said the couple paid about $10,000 
themselves. Most of the balance was covered by Dan’s employer-sponsored insurance with Anthem 
Inc. The insurance company declined to comment. Hospital charges are typically a starting point 
that insurers end up negotiating down. Payment records for Greulich’s seven-month stay at UCLA 
Medical Center show that Anthem paid at least $2.9 million.  
LONG ODDS. One day in February 2000, Dan Greulich failed to show up for work as a senior vice 
president of property and casualty insurer Western Mutual at the company’s Agoura Hills, 
California, office. His son, Tim, found him lying unconscious on the floor at home. At the hospital, 
doctors told Greulich that his liver and kidneys were failing, damaged beyond repair from his years 
of heavy drinking. He probably wouldn’t live more than a couple of months. His alcoholism 
disqualified him for a life-saving transplant. Greulich began attending Alcoholics Anonymous 
meetings while undergoing dialysis four times a week. “He completely gave up [alcohol] the second 
he went to that hospital,” Tim said. “He never picked up a drink after that.” By the end of 2000, he 
was on the transplant waiting list. The hospital entered his information into a computer system run 
by UNOS, the transplant coordinator, which uses information from hospitals and organ-
procurement groups across the country to match donors with recipients. The odds were against him. 
In 2001, the 6,080 people who died and became donors didn’t come near to covering the 86,000 
people waiting for organs. As Greulich waited, his health deteriorated. He struggled to make it 
through each workday. He spent lunch hours napping in his car. Then, in July 2002, he got his first 
transplant. Recovery, according to Rae, was complicated by his first encounter with superbugs: He 
contracted a MRSA infection, which kept him in the hospital until September. A month later, after 
about two years as a couple, Dan and Rae got married. Tim, Dan’s son from a previous marriage, 
lived with them. Dan returned to work, paring down his hours from 60 to 45 a week. He and Rae 
bought their dream home in Simi Valley, in the mountains 40 miles outside of Los Angeles. They 
had fruit trees in their backyard – lemon, orange, pomegranate – and kept horses. For nine years, 
Dan remained healthy and was “very religious” about taking his transplant medications, according 
to medical records.  In 2011, he began taking an herbal remedy called St. John’s wort to cope with 
stress at work. He didn’t know the plant could block the effects of anti-rejection drugs. On Dec. 6, 
nearly a decade after his first double transplant, Dan was back in UCLA Medical Center, his 
donated liver and kidney failing. He was soon relisted for a transplant. Again, as he waited, his 
health declined. On Jan. 5, 2012, medical records show, he was vomiting blood, and he was moved 
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to an intensive-care unit. He was charged the next day for his first night in the intensive-care bed: 
$10,400. His skin grayed. He spent more time sleeping. Every day, it seemed more likely that he 
would die before he made it to the top of the transplant list. In the early morning hours of Jan. 25, 
Rae received a call in her hotel room: A 40-year-old woman had died, and she was an organ donor. 
Dan was at the top of the waiting list. “Everything’s going to be OK,” Rae said she was thinking 
hours later, as Dan was wheeled into surgery. A second transplant is far more complicated and risky 
than the first, said Dr Fady Kaldas, an associate professor of surgery at UCLA specializing in liver 
transplants who was part of Dan’s medical team. Dan was losing so much blood during the 
operation that doctors spread the procedure over two days to give his body time to stabilize. At one 
point, Rae recalled, doctors told her they were losing Dan. He survived — one of 462 people to get 
a double transplant that year. His new liver soon began working on its own. His sister, Pat Herbert, 
said he told her he would make it to Florida for her birthday in May. His rosy colour returned. Even 
when his new kidney didn’t take, meaning he would have to rely on dialysis, he remained 
optimistic. Then, in early February, as nurses were removing post-surgical drains from Dan’s 
abdomen, a nauseating stench filled the ICU room, Rae recalled. Rae suspected something was 
awry. She was right. Dan’s medical records show that lab tests of fluid from the drains found two 
drug-resistant pathogens, Citrobacter freundii and Aeromonas. And they weren’t Dan’s first 
infections. He was already fighting a fungus called Candida albicans, which can be especially 
dangerous in transplant patients.  
MODERN DANGERS. Modern medical advances – complex organ transplants, drug therapies, 
devices such as ventilators and dialysis machines – sustain life for people who would otherwise die. 
But they come at a cost. They leave many people – cancer patients, people with HIV, premature 
infants, anyone with a suppressed or weakened immune system – particularly vulnerable to bacteria. 
At the same time, many of the bacteria that thrive in the hospitals where these people are 
concentrated have developed resistance to antibiotics. Dan Greulich was the perfect target. 
Transplant patients take drugs for the rest of their lives that suppress their immune systems so that 
their own bodies don’t reject the donor organs. That leaves them vulnerable to opportunistic 
pathogens like the two that showed up in Dan’s lab tests. Both rarely cause illness in otherwise 
healthy people; for the immune-compromised, they can be deadly. Hospitals have well-established 
protocols to contain the threat. At UCLA Medical Center, once Greulich tested positive for drug-
resistant infections, everyone – doctors, nurses, technicians, Rae, other relatives – had to don a 
gown and gloves before entering his room and discard them when leaving. Rae said she repeatedly 
asked nurses about Dan’s post-operative drains. They told her only that he had a fungal infection, 
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she said. No one told her the names of the pathogens, or that they were resistant to multiple drugs, 
or how dangerous they were. UCLA Medical Center declined to comment. Dan was now battling 
sepsis – life-threatening inflammation that is triggered throughout the body in a haywire response to 
infection. His blood pressure was abnormally low. His heartbeat was rapid and weak. Breathing was 
difficult, and he was often placed on mechanical ventilation, inserted through a tracheostomy, a 
hole surgeons cut into his windpipe. He was receiving dialysis through a port in his groin. He 
received fluids and drugs – including increasing amounts of ineffective antibiotics – through 
multiple tubes inserted into his veins and arteries. He was seldom lucid. Occasionally he would 
utter an “I love you” to Rae or ask how his recovery was going. Rae usually lied. “You’re doing so 
much better,” she would say, to encourage him to keep fighting. Doctors were desperate to locate 
the infection behind Dan’s sepsis. On Feb. 22, they wheeled him into surgery again and opened his 
abdomen, distended with retained fluid. This was risky in a patient so ill. “It’s not necessarily the 
easiest thing to take somebody who’s so stressed and sick and take them back to surgery,” Kaldas 
said. The surgery failed to reveal a definitive site of infection. Dan’s medical bills show at least 
$20,000 in related charges – for the operating room, the procedure, anesthesia and a liver biopsy. In 
March, Dan tested positive for a drug-resistant strain of Enterococcus. Unrelenting sepsis caused 
his body to swell. His skin was stretched tight and easily punctured. When Rae tried to clip his 
fingernails one day, he bled. Doctors had put Dan on drugs called vasopressors, which constrict 
blood vessels and thus raise the dangerously low blood pressure that sepsis causes. But that same 
mechanism also decreases essential blood flow to new organs, putting them at risk. “That’s what 
makes sepsis such an evil process … It just wreaks havoc on your body, including a delicate 
transplanted liver,” Kaldas said. “It’s always a game of what’s going to happen first. Are these 
organs just going to fall apart from being on vasopressors for a week, or is the infection going to go 
away first?” Another month, another infection. In early April, it was vancomycin-resistant 
Enterococcus (VRE), another common menace to hospital patients with weakened immune 
systems. A few days later, Rae recalled, two of Dan’s doctors sat down with her for a talk. Imaging 
showed that his new liver was a potential site of infection and a probable source of his sepsis. If 
they could clear Dan of the infections, they would consider him for a third liver-and-kidney 
transplant. In notes dated April 18, 2012, Dr Leonard Irwin Goldstein wrote that another transplant 
would provide “his best chance for long-term survival.” Only now, Rae said, did she realize that 
Dan’s struggle was not to recover from transplant surgery, but from a barrage of infections. 
“Nobody said he had a laundry list of infections,” she said. She started researching infection control 
and keeping a close eye on the nurses caring for Dan. In the ensuing weeks, she wrote three letters 
to the ICU’s nurse manager to urge vigilance against further infection and to list lapses she noticed 
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in her husband’s care. In a May 7 letter, she described stopping a nurse from starting an intravenous 
line when she saw that the nurse wasn’t going to change gloves after touching cabinet drawers and 
other potentially contaminated surfaces. UCLA Medical Center declined to comment. Since 
February, Dan had undergone increasingly aggressive antibiotic therapy. By the end of March, 
records show, he had been charged about $45,000 for the drugs. Then, for April alone, the amount 
ballooned to more than $110,000. Of that, $93,000 covered charges for 169 doses of Synercid, a 
combination of quinupristin and dalfopristin that is one of the few drugs that can beat back VRE. In 
just one day — May 2, 2012 — Dan was given six different antimicrobial drugs: amikacin, 
cefepime, daptomycin and Synercid, all of them commonly used to treat multi-drug-resistant 
infections; Bactrim; and caspofungin, an anti-fungal. Many of these drugs are hard on the body. The 
Synercid caused severe bone pain. Dan, who for months hadn’t complained about his pain, uttered 
to his wife, “I’m in agony,” according to Rae. At Rae’s request, doctors eventually stopped the 
drug. “Antibiotics beat you up,” said Kaldas. “Imagine somebody on nuclear weapons of 
antibiotics, and they’re on 10 of them, or five of them, or three of them. It’s a lot to ask.” By June, 
the continuing antibiotic therapy had left Dan nearly deaf. His hair had fallen out. On and off a 
ventilator, he had suffered several bouts of pneumonia. Unrelenting sepsis and the phenomenon 
known as ICU delirium – confusion and cognitive impairment associated with acute-care settings – 
left him incapable of recognizing little around him other than Rae and Tim. Doctors now said Dan 
would never be well enough for another transplant. He was going to die. They urged him to sign a 
“do not resuscitate” order. He refused. Rae posted a sign above his bed: “Mr. Greulich very clearly 
stated NO DNR and wants aggressive treatment.” For Dan’s medical team, giving up on a third 
transplant was an admission of defeat. “What we worry about is putting yet another organ into 
somebody that’s going to go the same way as the last organ,” said Kaldas. “You’ve developed a 
relationship with this patient … There’s nothing you want more than to see them get better. But you 
have to take a step back and say, well, a third liver will not make this person get better.” After 
months of illness, pain and confinement, Dan began to lose his will to live. He told Rae he felt 
worthless and that he knew he wasn’t ever going to recover. On June 29, Rae walked into his 
hospital room a little before 9 a.m., as she had nearly every day for the past seven months. He was 
sitting up in bed, alert and almost perky, she said. “I want to die,” he told her. The next day, Rae 
and Dan’s son, Tim, 24 years old at the time, stood at Dan’s bedside, holding his hands. They said 
their goodbyes. Just before 11:30 a.m., doctors turned off Dan’s dialysis machine. He soon lost 
consciousness. Rae and Tim watched as the tracing on Dan’s heart monitor slowed and slowed and 
then flat-lined. Greulich’s death certificate did not mention sepsis or the infections that caused it. 
His autopsy report, however, lists at least five pathogens present in samples taken from his body, 
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most of them drug-resistant. The report states: “The autopsy findings and microbiology studies 
support the clinical diagnosis of septic shock, which appears to be the immediate cause of death.” 
“It was clearer than anything that he died of septic shock,” Rae said. “When I got the death 
certificate, I was staggered.” 115  
 
3.1.2.  EXPERIMENTAL      
It is nowadays widely clear that antibiotic resistance is one of the biggest threats to global health, 
food security, and development today. Unfortunately, antibiotic resistance can affect anyone, of any 
age, in any country across the world. It can occur naturally, but misuse of antibiotics in humans and 
animals is accelerating the process. A growing number of infections – such as pneumonia, 
tuberculosis, gonorrhoea, and salmonellosis – are becoming harder to treat as the antibiotics used to 
treat them become less effective. According to facts reported in the introduction section of this 
chapter, antibiotic resistance leads to prolonged hospital stays, higher medical costs and, increased 
mortality. In my project, as mentioned in chapter 2 of this thesis, all the efforts have been focused 
on MRSA and Pseudomonas aeruginosa. In addition to this, a set of tests have been performed 
against Streptococcus mutans, the bacterium mainly responsible of tooth decay.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure . The rise of the Superbug. Courtesy of Dr S. Noimark and Dr K. Page – Chemistry Dept. 
University College London (United Kingdom).   
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Figure . The bacterium Pseudomonas aeruginosa. Source: Google Library, PubMed – NCBI.  
 
 
Figure . The bacterium Pseudomonas aeruginosa. Source: Google Library, PubMed – NCBI.  
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Figure . The bacterium Staphylococcus aureus. Source: Google Library, PubMed – NCBI.  
 
Figure . The bacterium Staphylococcus aureus. Source: Google Library, PubMed – NCBI.  
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Materials and methods: In order to prevent antibiotic resistant bacteria spreading not only inside 
hospitals, nurse houses but also public transports and schools; my research has been focused on the 
antimicrobial power of silver nanoparticles. In fact, in a study conducted in Lisbon – the capital of 
Portugal following a previous one in the city of Oporto (Portugal), has been documented the MRSA 
contamination of hand touched surfaces of public buses. The majority of the isolates belonged 
mainly to EMRSA-15 clone, MRSA New York/Japan clone and, MRSA USA300 or related clones. 
The first two clones are currently the two major lineages circulating in Portuguese hospitals! The 
conclusion of the study was that public buses in two major cities in Portugal are often contaminated 
with MRSA representing the dominant clones in hospitals in the particular geographic area. It has 
been clear that MRSA contamination of public transport and the transfer of the bacteria to the hands 
of passengers may represent a route through which hospital-acquired MRSA clones may spread to 
the community116. The spread of pandemic methicillin-resistant Staphylococcus aureus (MRSA) 
clones such as USA300 and EMRSA-15 is a global health concern. As a part of a surveillance study 
of three long-term care facilities in the Greater Chicago area, phenotypic and molecular 
characterization of nasal MRSA isolates was performed. In this American study it has been 
identified 22 EMRSA-15 isolates from 14 patients in three nursing homes that were sharing patients 
with some 40 acute care facilities in the region. Further, 12 of these 14 patients were residents of 
one nursing home, and their nasal carriage surveillance isolates accounted for 5.8% of all MRSA 
isolates identified at that facility. This study represents the evidence of the largest identified cluster 
of EMRSA-15 isolates observed in the United States, which is of concern since EMRSA-15 has 
been shown to replace previously predominant MRSA strains in Germany, Spain, Portugal, and 
Singapore117-120.  In 2017 the Kazan Federal University (Volga Region, Russia), discovered that S. 
aureus survives in P. aeruginosa biofilm under antimicrobial treatment conditions70. It has been 
experimentally demonstrated that exist synergistic interactions between P. aeruginosa and S. aureus 
in fact this one can produce lactate that is a carbon source that P. aeruginosa preferentially 
consumes over medium-supplied glucose69. In addition to this, the evidence suggests that P. 
aeruginosa – S. aureus infections are more virulent than monoculture infection with either 
species68.  
As detailed in chapter 2, silver has been recognized for its antimicrobial properties for centuries. 
Silver exerts a broad-spectrum antimicrobial effect against bacteria and, the development of 
bacterial resistance is rare and sporadic. Lots of studies on the antibacterial efficacy of silver, with 
particular emphasis on would healing, have been performed on planktonic bacteria121. With respect 
to chronic infections, however, the failure to achieve bacterial eradication with antimicrobial 
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measures is, as published by Bjarnsholt et al. 2007, due to the lifestyle bacteria adopt during chronic 
infections, namely the biofilm mode of growth. In this study it has been investigated the action of 
silver on mature in vitro biofilms of Pseudomonas aeruginosa (PAO1), a primary pathogen of 
chronic infected wounds. The experimental results showed that silver is very effective against 
mature biofilms of P. aeruginosa, but that the silver concentration is important. In fact, the 
bactericidal concentration of silver required to eradicate the bacterial biofilms was 10-100 times 
higher than that used to eradicate planktonic bacteria121.   
   
 
 
 
 
 
 
 
 
 
 
 
The antimicrobial activity of silver has been fully described by Dr J.A. Farwell in 1970, in his own 
manuscript entitled Sensitivity of Pseudomonas aeruginosa to silver, it has been reported that 
aqueous silver nitrate was effective against virulent pseudomonads invading burns (in burn therapy) 
and the results of such therapy were improved when non-viable tissue was continually removed 
from the burn area. A relationship between lethal action and concentration of silver ions was 
established and reported in 1932. Later, in 1940 it has been found that an organo-metallic complex 
was formed and that metallic oxides were also active and, the adsorption of the silver onto the cell 
surface lead to the formation of a metal-protein complex which was lethal to the bacterial cells. The 
action of silver is identical to that one proper of heavy metals, in fact they act in two stages: first, 
 
Figure . The SDS page of P. aeruginosa cells in planktonic and biofilm states122. Courtesy of Alfred B. 
Cunningham, John E. Lennox and, Rockford J. Ross – Montana U.S.A. Eds. 2001-2010.  
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adsorption onto the cell and second, reaction with essential cell components causing breakdown of 
metabolism followed by death123. Dr Farwell demonstrated that a direct relationship was shown 
between silver concentration and the percentage survival after 20 mins (P. aeruginosa suspensions). 
This relationship held over the range 5×10-6M – Ag+ to 3×10-5M – Ag+.  Above this level a 
maximum die-off was obtained. The time taken for a 30% drop in viable count also decreased with 
increased silver concentration to a minimum at similar concentrations to that at which the die-off 
was maximum. It was clear that P. aeruginosa stored suspensions of non-depleted cells and, 
magnesium depleted suspensions survived better than those cells depleted of the carbon source – 
glucose (the adsorbed magnesium on the cell wall aided survival of stored suspensions). In fact, it 
has been found that P. aeruginosa did not lay down storage products even when conditions 
favoured this and also that, when the cells became carbon or nitrogen depleted in the growth 
medium, ribosomal degradation occurred. These depleted cells, stored in buffer, showed loss of 
viability as well as decrease in RNA and DNA but non-depleted cells showed an initial rise in count 
under the same conditions. Preliminary experiments with silver treated cells suggested that leakage 
occurred, and that this leakage was a result of silver action (and not of cell death). This implied that 
silver had an effect on the permeability mechanism of the cell and this had been reported in 1963 
when it has been attributed the stimulation of Neurospora respiration by silver to increased 
permeability123. More recently, on Nature in 2015 it has been explained the antibacterial activity of 
silver-killed bacteria. It has been reported a route for the prolonged action of silver (biocidal agent) 
that has not been previously recognized and, that Wakshlak RB. et al. 2015 called the “zombies 
effect”: bacteria which were killed by silver show significant biocidal activity towards viable 
population of the same bacterium. The origin of this phenomenon is in two characteristics of the 
metal-induced biocidal action: first, the metallic species are not deactivated by the killing 
mechanism and, therefore can carry on their biocidal effect repeatedly; and second, the dead 
bacteria serve as an efficient sustained release reservoir for releasing the lethal metallic cations for 
further action against other living bacteria. It has been experimentally demonstrated that biocidally-
killed bacteria are capable of killing living bacteria. This concept is demonstrated by first killing 
Pseudomonas aeruginosa (PAO1) with silver nitrate and then challenging, with the dead bacteria, a 
viable culture of the same bacterium: an efficient antibacterial activity of the killed bacteria is 
observed. A mechanism is suggested in terms of the action of dead bacteria as a reservoir of silver, 
which, due to Le-Chatelier's principle, is re-targeted to the living bacteria124. The so-called 
“zombies effect” of Pseudomonas aeruginosa is shown in the following figure.  
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It is widely clear that today the two most problematic nosocomial pathogens are Pseudomonas 
aeruginosa and Staphylococcus aureus and, both often express multidrug resistance. A number of 
case-control studies at individual hospitals (it has been measured fluoroquinolone use from 1999 
through 2003 in a network of hospitals in the USA) have identified fluoroquinolone use as a risk 
factor for acquisition of fluoroquinolone-resistant P. aeruginosa and methicillin-resistant S. aureus 
(MRSA)125. To cope with the problem, a series of samples were prepared for microbiological 
testing using a similar two-step dipping method as previously described in chapter 2. A simple 
swell-encapsulation-shrink process was employed to incorporate crystal violet (CV) dye and silver 
nanoparticles (Ag NPs) into polyurethane using acetone as a swelling solution. In the swell-
encapsulation process, the CV molecules and Ag NPs in the acetone penetrate the polyurethane 
matrix as it swells, and the polyurethane then shrinks when it is removed from the solution. The CV 
molecules and Ag NPs remain inside of the polyurethane matrix. But this time the silver 
nanoparticles solution described in chapter 2 (citrate-capped silver) was triple concentrated and, 
 
Figure . The zombies effect of PAO1. TEM (bright background) and STEM (dark background) of P. 
aeruginosa before (a and d) and after (b, c, and e) treatment with silver: the black (b) and white (e) granules 
represent silver deposition which account for the “zombies” biocidal action. Courtesy of Wakshlak RB., 
Pedahzur R., Avnir D., Nature – Scientific Reports, 2015.  
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following the method published by Lambadi P. et al. 2015, a biofunctionalized with polymyxin B 
silver nanoparticles solution was also prepared. The polymyxin B is an antibacterial peptide126.  
Antimicrobial peptides (AMPs) have been identified in most living organisms (such as bacteria, 
fungi, plants, invertebrates and vertebrates including humans) as an important component of their 
natural defences. They form the first line of host defence against pathogenic infections and are an 
evolutionarily conserved component of the innate immune system. These peptides are potent broad-
spectrum antibiotics, they are synthesized constitutively at epithelial surfaces that is the location 
where the initial contact will all microorganisms takes place85.   
Preparation of chemical stock solutions. The crystal violet solution – solution A was prepared 
dissolving 60mg of crystal violet powder (CV, Sigma-Aldrich, St. Louis, MO, USA) in 100ml of a 
solution containing 10ml of DI water and 90ml of acetone. The solution was sonicated in an 
ultrasound bath for 5 min in order to ensure complete dissolution of CV powder. The solution B 
was prepared dissolving 45mg (0.26mM) ×3 of AgNO3 (Silver nitrate, Sigma-Aldrich, St. Louis, 
MO, USA) in 50ml of DI water to produce an approximately 5mM solution. The solution C was 
prepared dissolving 294.7mg (1mM) ×3 of Na3C6H5O7∙2H2O (tri-sodium citrate dihydrate, Hopkin 
& Williams Ltd, London, UK) in 50ml of DI water to form a 20mM solution. Synthesis of silver 
nanoparticles was prepared mixing 10ml of solution B with 180ml of DI water and heated with 
constant stir. After the mixture was boiled for ⁓ 2 min, 10ml of solution C was added. With 
constant stir, the mixture was boiled for a further 30 min and then allowed to cool. The 
development of a dark-brown colour was observed during the process. The biofunctionalized with 
polymyxin B silver nanoparticles solution (solution D) was prepared by the addition of freshly 
prepared silver nitrate (2 mM) and NaBH4 (0.6 mM) to a polymyxin B solution in methanol (Silver 
nitrate, sodium borohydrate, polymyxin B, methanol, Sigma-Aldrich, St. Louis, MO, USA). The 
resultant mixture was incubated for 0–30-minute time periods at 30°C under illumination at 40 W 
yellow light (141.3 lux) as published by Lambadi P. et al. 2015. The development of a yellow 
colour was observed during the process. The prepared polymyxin B-capped silver nanoparticles 
(PBSNPs) were dialyzed against milli-Q water for 12 hours using a 10 kDa cut-off membrane to 
remove unbound polymyxin B and free silver ions. The unbound polymyxin B was removed from 
PBSNPs by passing the sample through a 10 kDa molecular weight cut-off spin-filter (Vivaspin, 
Vivaproducts, Inc., Littleton, MA, USA). The morphology and size of silver nanoparticles were 
observed using TEM (JEM-2100, JEOL Inc., Peabody, MA, USA).  The presence of polymyxin B 
on the surface of silver NPs and the effect of attachment on the secondary structure of peptide were 
measured with FTIR (Thermo Nicolet NEXUS 670 FTIR; GMI, Ramsey, MN, USA) and CD 
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spectroscopy (Chirascan™ CD Spectrometer; Applied Photophysics Ltd, Leatherhead, UK), 
respectively. Free polymyxin B and citrate-capped nanoparticles were used as control as published 
by Lambadi P. et al. 2015.   
Preparation of white light-activated antimicrobial surface. Polyurethane squared samples 
(1.0×1.0cm) were immersed in 10ml of acetone solution and left to swell in the dark for 24 h and 
then still wet, were immersed in solution A (CV solution) and left to swell in the dark for 24 h. The 
samples were recovered from the CV solution and washed using a DI water bath sonicator for 2 
times and then air-dried for 24 h in the dark. The samples were prepared as follows: CV only, CV 
with Ag NPs. Additionally, NPs encapsulated polyurethane samples without CV – polyurethane 
with Ag NPs, were prepared as follows: polyurethane squared samples (1.0×1.0cm) were immersed 
in 10ml of acetone solution and left to swell in the dark for 24 h and then still wet, were immersed 
in the two silver NPs solutions prepared (half in citrate-capped silver NPs solution and half in 
polymyxin B-capped silver NPs) and, left to swell in the dark for 24 h. Then samples were air-dried 
for 24 h in the dark.  
Material characterization. This part has been performed accordingly with Chapter 2 of this thesis: 
TEM analysis of silver nanoparticles revealed that both citrate-capped silver NPs and polymyxin B-
capped silver NPs were spherical in shape with different diameters; citrate-capped Ag NPs ⁓43nm 
and, polymyxin B-capped Ag NPs ⁓15nm.   
The UV-vis absorption spectra against NPs suspensions, control and treated samples were measured 
using UV-vis Spectrometer (PerkinElmer Inc., Winter St., CT, USA). Absorption was measured 
from 350 to 900nm. To determine NPs uptake from NPs suspension to polyurethane, the UV-vis 
spectra of NPs suspension were measured before and after swell-encapsulation-shrink process. The 
polymer sample was immersed in a mixture of acetone (9ml) and NPs (1ml) for 24 h. The 
comparison of absorbances before and after at 409nm (citrate-capped Ag NPs) and at 414nm 
(polymyxin B-capped Ag NPs) was enable determination of the total amount of NPs absorbed in the 
polyurethane samples after the treatment. 
 
 
 
 
                   
Figure . TEM photos selection of my silver nanoparticles. Courtesy of UCL laboratories.  
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Antimicrobial tests. To examine the antimicrobial activity, a range of polyurethane samples 
(1.0×1.0cm) was used to perform the experiments: acetone treated polyurethane (control), crystal 
violet-coated polyurethane, crystal violet-coated nano-silver encapsulated polyurethane, and nano-
silver encapsulated polyurethane. These samples were tested against Epidemic MRSA 4742 
representative of a Gram-positive epidemic bacteria (isolated at UCL Hospital) and Pseudomonas 
aeruginosa PAO1 representative of Gram-negative bacteria resistant to the majority of currently 
used antibiotics (ATCC – LGC Standards, Middlesex, England, UK). These organisms were stored 
at – 70°C in Brain-Heart Infusion broth (Oxoid Ltd, Hampshire, England, UK) containing 20% 
(v/v) glycerol and propagated on Mannitol salt agar and Cetrimide agar (Oxoid Ltd, Hampshire, 
England, UK) respectively, according to the British Pharmacopoeia 2018 (Ed.).  
BHI broth (10ml) was inoculated with one bacterial colony and cultured in air at 37°C for an 
incubation of 18 h with shaking, at 200 rpm. The bacterial pellet was recovered by centrifugation 
(21°C, 2000×g, 5 min), washed in phosphate buffered saline (PBS) and centrifuged again to recover 
the bacteria, which were finally re-suspended in PBS (10ml). The 2 times washed suspension was 
diluted 1000-fold in PBS to obtain the inoculum. The inoculum contained 4.6×106 colony forming 
units per mL (CFU mL-1). The inoculum in each experiment was confirmed by plating ten-fold 
serial dilutions on agar for viable counts. Duplicates of each polymer sample type were inoculated 
with 25L of the inoculum (containing 1.1×105 CFU) and covered with a sterile cover slip 
(22mm×22mm) to ensure good contact between the bacteria and the sample surface. The samples 
were placed into plastic petri dishes containing moistened filter paper to maintain humidity at room 
temperature. The samples were then irradiated for up to ⁓5 hours using a white light source, the 
white light intensity was measured using a lux meter (LX-101, Lutron Inc., Coopersburg, PA, USA) 
at a distance of 30cm from the light source. The intensity of the light ranged from 390 to 530 lux. A 
further set of samples (in duplicate) was maintained in the dark for the duration of the irradiation 
time. In the dark, the light was completely blocked (0 lux). After light exposure, the inoculated 
samples and cover slips were placed into 450l of PBS, and mixed using a vortex mixer for 1 min. 
The neat suspension and ten-fold serial dilutions were plated on Mannitol salt agar and Cetrimide 
agar respectively for viable counts. The plates were incubated aerobically at 37°C for 24 h. Finally, 
the colonies grown on these plates were counted. All experiments, unfortunately, could not be 
reproduced three times for each bacterial type because the time was not enough.    
Results and discussion: In this work it has been used a “facile method” to develop a polymer 
encapsulated with a phosensitiser dye in addition to silver nanoparticles.  In the first step, the 
polyurethane samples were immersed in an acetone swelling solution.  In the subsequent step, the 
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same samples sill wet, were immersed in a crystal violet solution for 24 h, another amount of 
samples in a 9:1 crystal violet solution : nano-silver solution for 24 h, and another amount in a 
nano-silver solution for 24h under dark conditions. Upon exposure to the solvent, the polymer 
swells enabling the dye molecules to diffuse through the polymer.  
The antimicrobial activity of the control, CV dyed polyurethane samples, CV dyed and nano-silver 
encapsulated polyurethane samples and nano-silver encapsulated polyurethane samples under white 
light and dark conditions was tested against a representative strain of the Gram-positive bacterium, 
MRSA and, against a representative strain of the Gram-negative bacterium Pseudomonas 
aeruginosa. The data (of the first experiments performed) show that the antimicrobial activity of the 
polymers was promoted by exposure of the samples to a white hospital light source; a compact 
fluorescent lamp which emits light across the visible region of the spectrum and is similar to those 
commonly found in the UK NHS hospitals. In all experiments, a control sample set was maintained 
under dark conditions for the same period of time as the samples exposed to light and, in a further 
experiment, a sample set was incubated under dark conditions for an extended time period (24 h). 
The antimicrobial activity of crystal violet-coated polyurethane (CV only), crystal violet-coated 
nano-silver encapsulated polyurethane (CV Ag) and nano-silver encapsulated polyurethane (Ag 
only) was compared to that of a control, solvent treated polyurethane sample. The lethal 
photosensitization induced by these samples when exposed to a white light source emitting an 
average light intensity of ⁓500 lux at a distance of 30 cm from the samples for ⁓5 h is shown in 
Figure.  
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Figure . Antimicrobial activity of 
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After 5 h at 500 lux, no reduction in the numbers of viable bacteria of MRSA 4742 was observed on 
the surfaces of the control material (polyurethane alone) and the nano-silver encapsulated 
polyurethane (Ag only). However, a statistically significant (P-value < 0.01) decrease in the number 
of viable bacteria was observed on the material containing crystal violet alone (2.48 log reduction in 
bacterial numbers) and crystal violet with Ag NPs (2.48 log reduction). After 5 h in dark conditions 
no significant reduction has been found in all samples, however after 24 h in the dark polyurethane 
containing CV alone and CV with Ag NPs showed a significant reduction in the numbers of 
bacteria below the limit of detection (P-value < 0.01, detection limit: below 102 CFU mL-1). 
Additionally, in experiments of polyurethane containing Ag NPs only, no reduction in the number 
of viable bacteria was confirmed after 5 h incubation in the dark. An additional decrease of viable 
bacterial colonies has been found by using samples coated with the biofunctionalized silver 
nanoparticles (PBSNPs) after 5 hours at 500 lux and after 5 hours in dark conditions. However, 
after 24 h in dark condition, a significant reduction was observed on both polyurethanes coated with 
Ag NPs (P-value < 0.01, detection limit: below 102 CFU mL-1).  
Concerning the antimicrobial activity of the polyurethane samples against the Gram-negative 
bacterium P. aeruginosa, at the same light and dark conditions used for the MRSA, the following 
data has been found as shown in Figure .  
 
 
 
 
 
 
 
 
After 5 h at 500 lux, no reduction in the numbers of viable bacteria of PAO1 was observed on the 
surfaces of the control material (polyurethane alone), polyurethane with only CV and polyurethane 
containing CV and Ag NPs. However, a statistically significant (P-value < 0.01) decrease in the 
number of viable bacteria was observed on the material containing Ag NPs alone (2.18 Log 
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reduction). After 5 h in dark conditions no significant reduction has been found in all samples, 
however after 24 h in the dark polyurethane containing only Ag NPs showed a significant reduction 
in the numbers of bacteria below the limit of detection (P-value < 0.01, detection limit: below 102 
CFU mL-1). Additionally, in experiments of polyurethane containing only CV and CV with Ag 
NPs, no reduction in the number of viable bacteria was confirmed after 5 h and 24 h of incubation 
in dark conditions. A similar situation has been found performing the same experiments using 
samples coated with the biofunctionalized silver nanoparticles (PBSNPs) after 5 hours at 500 lux 
and after 5 hours in dark conditions. Only after 24h all the viable colonies were totally destroyed.  
As described in chapter 2, the XPS analysis of all samples confirmed that silver NPs remain inside 
of the polyurethane matrix and, consequently nothing has been found on the samples surface.   
 
 
 
 
 
 
 
 
 
These initial experimental results were expected, although unfortunately there was not enough time 
to reproduce them three times for each bacterial type. According to Lambadi P. et al. 2015, it has 
been found that polymyxin B-capped silver nanoparticles had more antibacterial power than citrate-
capped silver nanoparticles against planktonic cells of MRSA (gram positive bacterium) and 
Pseudomonas aeruginosa (gram negative bacterium). Apart from the antibacterial activity, it has 
been investigated the role of polymyxin B on PAO1 biofilm formation. Antimicrobial peptides 
(AMPs) have recently emerged as excellent antimicrobial agents to address multidrug resistance in 
bacteria. They act damaging the bacterial cell membrane at low concentrations. AMPs can also 
stabilize silver NPs by exerting a polyvalent effect, in fact they form layers on the surface of silver 
NPs and thus they can prevent agglomeration127-130. The biofunctionalized silver NPs used in this 
              
Figure . TEM images of silver nanoparticles; A: citrate-capped Ag NPs (courtesy of UCL laboratories) 
and B: polymyxin B-capped Ag NPs (courtesy of Prof Navani NK. – Indian Institute of Technology, 
Roorkee, Uttarakhand, India).     
A B 
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study, said Lambadi P. et al. 2015, clearly showed an extensive damage of the bacterial cell 
membrane in the presence of PBSNPs and, consequently a decrease in MIC as compared with 
citrate silver NPs for their antibacterial activity against both antibiotic-resistant bacteria. They 
observed the cellular growth at OD600 after 10 hours. Growth above 10% of the OD at 600 nm 
(OD600) of the positive control (lacking any antimicrobial agent) was considered uninhibited 
growth. MIC is the lowest concentration of PBSNPs that inhibited the visible growth of 
microorganisms. CSNPs with the same concentration were taken as a control126. The plausible 
explanation for the damage is that highly cationic polymyxin B peptides first get attached to the 
bacterial surface and make small and transient ion-permeable holes that disturb the functions of the 
bacterial membrane. Subsequently, the combined action of SNPs and polymyxin B led to a 
complete rupture of the bacterial membrane, resulting in leakage of the cell contents and finally cell 
death131. These results indicate that the enhanced antibacterial activity of PBSNPs was due to the 
presence of polymyxin B molecules on the surface of SNPs. The interaction of these conjugates 
provided an opportunity for both agents to act on the bacteria simultaneously, thus enhancing its 
inhibitory effect132. Polymyxin B is known to interact with the LPS part of lipid A of Gram-
negative bacterial cell walls. LPS is also known as endotoxin, which is shed by Gram-negative 
bacteria and is notorious for causing sepsis and septic shock133.  The PBSNPs efficiently removed 
endotoxin from the test samples (~97%) as compared with control (~16%). The efficient removal of 
endotoxin could be attributed to the polymyxin molecules present on SNPs owing to their enhanced 
surface-to-volume ratio as compared with the conventional column matrix134.  Finally, Lambadi P. 
et al. 2015, reported that biofunctionalized silver nanoparticles were found to resist PAO1 biofilm 
formation. The ability of these functionalized nanoparticles for their antibiofilm activity against P. 
aeruginosa was tested: upon the exposure of PAO1 cells to MIC of PBSNPs (4.5μg Ag0/mL) and 
CSNPs (12.5μg Ag0/mL), a complete inhibition of bacterial growth (OD600) occurred, with the 
disappearance of biofilm formation (OD550) after 6 hours of incubation. These results reveal that 
PBSNPs display ~3-fold higher antibiofilm activity as compared with CSNPs, suggesting a 
paramount role being played by the capping agent polymyxin B. Concurrent inhibition of 
planktonic cell growth and biofilm formation with increasing concentration of PBSNPs suggests 
that this formulation is refractory to the establishment of bacterial biofilm likely due to inhibition of 
planktonic cells126, as showed in the following figure kindly shared by Prof Naveen Kumar Navani 
research group – Indian Institute of Technology, Roorkee, Uttarakhand, India.    
 
 
86 
 
 
 
 
 
 
 
 
 
The last experiment that has been performed by using silver nanoparticles has been against 
Streptococcus mutans 25175 (ATCC – LGC Standards, Middlesex, England, UK), the Gram-
positive bacterium mainly responsible of tooth decay. Unfortunately, there was not enough time left 
to reproduce the experiment three times, hence only the initial results have been collected. It has 
been applied the same method and, the same materials used to test the other two bacteria mentioned 
above. The bacterium has been plated on Columbia blood agar for viable counts (Columbia Agar 
Base – Lab M Ltd, Lancashire, England, UK + 5% defibrinated horse blood – E&O Laboratories 
Ltd, Bonnybridge, Scotland, UK).  
A set of samples (in duplicate): the acetone treated polyurethane (control), CV dyed polyurethane 
samples, CV dyed and nano-silver (CSNPs) encapsulated polyurethane samples and nano-silver 
(CSNPs) encapsulated polyurethane samples have been tested at ⁓500 lux and under dark 
conditions (0 lux) for up to 5 hours against a strain of Streptococcus mutans. In addition to it, a 
sample set (in duplicate) was incubated under dark conditions for an extended time period (24 h). 
The results obtained were pretty much identical with that ones collected for MRSA. After 5 h at 500 
lux, no reduction in the numbers of viable bacteria of Streptococcus mutans was observed on the 
surfaces of the control material (polyurethane alone) and the nano-silver encapsulated polyurethane 
(Ag only). However, a statistically significant (P-value < 0.01) decrease in the number of viable 
bacteria was observed on the material containing crystal violet alone (2.49 log reduction in bacterial 
numbers) and crystal violet with Ag NPs (2.49 log reduction). After 5 h in dark conditions no 
significant reduction has been found in all samples, however after 24 h in the dark polyurethane 
containing CV alone and CV with Ag NPs showed a significant reduction in the numbers of 
bacteria below the limit of detection (P-value < 0.01, detection limit: below 102 CFU mL-1).  
 
Figure . The PBSNPs inhibition of biofilm formation of PAO1 cells. Courtesy of Prof Navani NK. – 
Chemical Biology Laboratory, Department of Biotechnology and Centre of Nanotechnology, Indian 
Institute of Technology, Roorkee, Uttarakhand, India.  
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Additionally, in experiments of polyurethane containing Ag NPs only, no reduction in the number 
of viable bacteria was confirmed after 5 h incubation in the dark. However, after 24 h in dark 
condition, a significant reduction was observed on polyurethanes coated with Ag NPs (P-value < 
0.01, detection limit: below 102 CFU mL-1).  Unfortunately, there was not enough time to test the 
samples coated with the biofunctionalized silver nanoparticles (PBSNPs) after 5 hours at 500 lux 
and after 5 and 24 hours in dark conditions (0 lux).   
 
 
 
 
 
 
 
 
These results, although they are not enough at the moment, were expected. According to Prof M. 
Nisnevitch – Ariel University Israel, an alternative approach to the eradication of bacteria is based 
on photodynamic treatments with the help of photosensitizers, which are dye compounds capable of 
transferring the energy of absorbed visible light to surrounding bio-organic molecules (called a 
Type I photodynamic reaction) or to dissolved oxygen (called a Type II photodynamic reaction). 
The Type I reaction includes excitation of photosensitizers upon illumination at an appropriate 
wavelength and energy transition to organic substrates, thus, producing active free radicals and 
radical ions. The Type II mechanism differs from the Type I in the second stage of action, where 
energy is transferred from the photosensitizers to oxygen molecules, exciting them and causing the 
formation of reactive oxygen species. The active products in both cases cause direct and indirect 
damage to cellular components, such as membrane phospholipids and proteins, leading to 
membrane leakage, cytolysis, and death of pathogenic cells135-138. It has been reported by Strømme 
M. et al. 2012, that bacteria in biofilms better survive harsh environmental conditions and, 
consequently these bacteria compared to the planktonic ones have a 10 – 1000 times higher 
resistance towards antibiotics. This has become a major healthcare concern as antibiotic-resistant 
bacterial strains like methicillin-resistant Staphylococcus aureus (MRSA) are appearing. Multiple 
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factors contribute to this resistance, including physical and chemical diffusion barriers, reduced 
sensitivity towards antibiotics due to the slow growth rate of bacteria in biofilms, as well as the 
structural heterogeneity within biofilms and development of biofilm-specific biocides-resistant 
bacteria phenotypes. Furthermore, biofilms are often associated with implants (e.g. dental implant) 
or other biomaterials as such biocompatible materials also provide an ideal substrate for biofilm 
formation. Understanding biofilms and the antibacterial methods for their removal of inhibition is 
thus critical in the development of functional biomaterials. The specific growth rate of 
Streptococcus mutans bacteria in biofilm mode of growth has been found by Strømme M. et al. 
2012, and it was 0.70h-1, compared to 1.09h-1 in planktonic growth. The applied method has been 
based on the derivation of the specific growth rate of Streptococcus mutans bacteria biofilm from a 
series of metabolic assays using the pH indicator phenol red and, it has been demonstrated that this 
information could be used to more accurately quantify the relative number of viable bacteria in a 
biofilm139.  The Department of oral biology of the Buffalo University – New York (USA) 
investigated the susceptibility of selected bacteria as well as Streptococcus mutans biofilm to 
MUC7 peptides and compared the activities with those of other known antimicrobial peptides. 
Among the antimicrobial peptides, histatin and mucins are two families of human salivary proteins 
that form the innate immunity system, a first-line of the host defence system against pathogens. 
Histatins and histatin-derived peptides have been shown to possess a significant in vitro 
antimicrobial activity against fungi, bacteria, and bacterial biofilms. The low molecular mass 
human salivary mucin – MUC7 (357 amino acid residues), protects the oral cavity from microbial 
infections through more general protective mechanisms (such as binding to and clearance of various 
microorganisms) rather than the direct killing of microorganisms. Dental caries and periodontitis 
are common oral diseases: Streptococcus mutans is the main pathogenic agent of dental caries and, 
Porphyromonas gingivalis and Actinobacillus actinomycetemcomitans are the bacteria associated 
with periodontitis. The prevention of dental caries and periodontal disease requires the control of 
these pathogens that exist in an oral biofilm known as dental plaque. The MIC and MBC of 
peptides for S. mutans, Escherichia coli, Streptococcus gordonii, Actinobacillus 
actinomycetemcomitans, Porphyromonas gingivalis and Pseudomonas aeruginosa were determined 
by Wei GX. et al 2006, using the microdilution method. For S. mutans, the effects of the peptides 
on the kinetics of growth inhibition, time-killing and, on biofilm formation and reduction were also 
examined. The experimental results carried out showed that S. mutans was the most susceptible to 
all peptides tested (MICs of 9.4-25.0 microM), compared with the other species (MICs of 3.1->100 
microM). The MUC7 peptides (except MUC7-12-mer-L4) exerted 2-fold higher activity against S. 
mutans than Hsn5-12-mer and magainin-II, and faster killing of S. mutans than Hsn5-12-mer. The 
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MUC7 peptides also had an effect on S. mutans biofilm. One day developed biofilm viabilities were 
inhibited by 49-75%. On hydroxylapatite discs, the formation of biofilm was also considerably 
reduced. The MUC7 peptides present somewhat preferential antimicrobial activity against S. 
mutans and, they also influence in vitro formation and reduction of the preformed Streptococcus 
mutans biofilm140.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          
Figure . The bacterium Streptococcus mutans. Source: Google Library, PubMed – NCBI.  
Streptococci and oral streptococci (2011) retrieved from the Oral Environment website: 
http://www.ncl.ac.uk/dental/oralbiol/oralenv/tutorials/streps.htm and (2012) retrieved from American 
Dental Association website: www.gsa.ada.org   
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Figure . The bacterium Streptococcus mutans (images A, B). Source: Google Library, PubMed – NCBI.   
B 
Figure . The mouth microbes. Source: Google Library, PubMed – NCBI.   
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3.1.3.  CONCLUSION   
It is widely clear nowadays that infectious diseases cause a huge burden on healthcare systems 
worldwide and, that pathogenic bacteria establish infections by developing the antibiotic resistance. 
Unfortunately for us, they can also modulate the host’s immune system, whereas opportunistic 
pathogen bacteria like Pseudomonas aeruginosa adapt to adverse conditions owing to their ability 
to form biofilms. Infections associated with surgical devices and medical implants pose persistent 
and severe problems that account for high morbidity in hospital settings. The Center for Disease 
Control and Prevention (CDC) estimated that surgical site infections account for ⁓22% of hospital-
acquired infections141. Synthesis of nanomaterials holds infinite possibilities as nanotechnology is 
revolutionizing the field of medicine by its myriad applications. Silver nanoparticles demonstrated 
to have the power to overcome this growing problem. It has been shown that combined antibacterial 
action of silver nanoparticles and polymyxin B in solution exerts a synergistic effect on bacterial 
pathogens; briefly, the antimicrobial effectiveness of silver nanoparticles is enhanced by the 
antimicrobial peptide polymyxin B. In other words, the power of silver has been increased by 
synthesizing biofunctionalized silver NPs. Moreover, the antibacterial property of the polymyxin B-
capped silver nanoparticles did not alter significantly over a period of 1 month142. It is also clear 
that photosensitizers, which are dye compounds capable of transferring the energy of absorbed 
visible light to surrounding bio-organic molecules or to or to dissolved oxygen, can be activated by 
white light causing the death of bacteria cells. This can be very useful limited to dermatologic and 
dental problems. The development of efficient antibacterial coating has been recognized as a major 
challenge in mitigating biofilm formation and controlling the infectious agents in hospital settings.  
Future work will be focused on carrying on the missing experiments on antibiotic resistance 
bacteria to select the best coating material to kill them. Green synthesis of nanoparticles has become 
the need of the hour because of its eco-friendly, nontoxic, and economic nature. It will be very 
challenging to produce silver nanoparticles by using the leaf extract of Rosa damascena as a bio-
reductant to reduce silver nitrate, as detailed by Ahmad N. et al 2015, leading to synthesis of silver 
nanoparticles (AgNPs) in a single step, without the use of any additional reducing or capping 
agents143. The relatively higher stability of nanoparticles produced by plant sources as compared to 
microbial ones further tip the scales in favor of synthesis utilizing plant sources. Various plants can 
be employed for the nanoparticle synthesis such as Cinnamomum camphora, Medicago sativa, 
Pelargonium graveolens, Avena sativa, Azadirachta indica, Tamarindus indica, Emblica officinalis, 
Aloe vera, Coriandrum sativum, Carica papaya, Parthenium hysterophorus, Acanthella elongata, 
Sesuvium portulacastrum, Chrysanthemum indicum L, Melia azedarach L, Saraca indica, 
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Caesalpinia coriaria, Vitex negundo L. Biomolecules like honey can also be used for the synthesis 
of e.g. gold nanoparticles. Because of their submicroscopic size and unique material characteristics, 
manufactured nanoparticles may find practical applications not only in engineering, but also in 
medicine143 especially in dentistry in fact it will be possible to manufacture antimicrobial aligners 
or similar (e.g. Invisalign®) to help preventing gingival inflammation and tooth decay.  
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3.2 Antibacterial activity in Manuka Honey   
3.2.1. INTRODUCTION  
Honey has been used as a medicine throughout the history of the human race, its medical use is 
already reported in the British Pharmacopoeia 2018 (Ed.)144. Among monographies, it is reported 
the European Pharmacopoeia monograph 2051 in which honey is defined as produced by bees (Apis 
Mellifera L.) from the nectar of plants or from secretions of living parts of plants which the bees 
collect, transform by combining with specific substances of their own, deposit, dehydrate, store and 
leave in the honey comb to ripen and mature. Production: if the bee has been exposed to treatment 
to prevent or cure diseases or to any substance intended for preventing, destroying or controlling 
any pest, unwanted species of plants or animals, appropriate measures are taken to ensure that the 
levels of residues are as low as possible. Characters – appearance: viscous liquid which may be 
partly crystalline, almost white to dark brown144-145. The British Pharmacopoeia 2018 (Ed.) defines 
Apis Mellifera L. as follows, the body is about 15mm long, black, with a silky sheen, and covered 
with red hairs with a touch of grey. The broad tibiae are without spines. The posterior margins of 
the segments and legs are brown, with gradual transition to orange-red. The claws are two-
membered, the maxillary palps single-membered. On the hind legs are baskets or scoops invested 
with bristles. The wings have 3 complete cubital cells, with the radial cell twice as long as it is 
wide; the 3 cells on the lower margin and the 3 middle cells are closed. A duct connects the barbed 
sting with the poison sac144.    
 
 
 
 
 
 
 
 
 
Figure . The Apis Mellifera 
L. of Waikato region (NZ). 
Courtesy of Dr Megan 
Grainger – University of 
Waikato, Hamilton, NZ.  
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As clearly described by Dr Jonathan Stephens in his own manuscript published by the University of 
Waikato, Hamilton, NZ in 2006, honey has continued to be employed as a traditional therapy in 
many parts of the world, however it fell from favour in Western society with the development of 
modern antibiotics (Molan 1999a). One of the most common and persistent therapeutic uses of 
honey has been as a wound dressing, almost certainly due to its antimicrobial properties.  A 
resurgence of interest in honey has led to an explanation of the reported medical properties. Honey 
has different actions as a treatment, and whilst the principle agent of healing is antibacterial 
activity; anti-inflammatory action, stimulation of the immune system, stimulation of cell growth, 
and antioxidant activity all enhance the therapeutic properties (Molan 1999b, 2001a). The literature 
describing the effect of honey on a wide range of bacterial species and its effectiveness in healing 
infected wounds has been recently reviewed (Molan 2001b). The antibacterial activity of honey has 
been extensively researched and is found to contain four components. The main factor is hydrogen 
peroxide, termed inhibine until correctly identified (White et al. 1962). Hydrogen peroxide is 
generated by glucose oxidase, an enzyme added to the nectar during concentration by the honeybee 
(Apis mellifera) from its hypopharyngeal gland (White et al. 1963). The concentration of hydrogen 
peroxide may be related to the dominant floral source, as ascorbic acid, metal ions and catalase 
found in varying quantities in nectar all contribute to hydrogen peroxide degradation (Molan 1997). 
The enzyme is also sensitive to heat and light denaturation, the sensitivity to both dependent to 
some extent on the floral source (Molan 1997). Two other antibacterial factors are common to 
honey, the effect of osmolarity and acidity. The water content of honey varies between 15–21% 
w/v, however due to the interaction between water molecules and the monosaccharide component 
only a small and insufficient fraction of the water is available for the growth of bacteria (Molan 
1992). Likewise, the relatively high acidity of honey is antibacterial: the acidity varies between pH 
3.2–4.5 and is beyond the lower limits for growth of most animal pathogens (Molan 1997). The 
fourth component does not appear to be universal in all honey types. Early work found antibacterial 
activity remained after the removal of hydrogen peroxide by the addition of catalase (Adcock 
1962), and the non-peroxide antibacterial activity was reported to be a minor proportion of total 
antibacterial activity (Dustman 1979). Antibacterial fractions were recorded in water, alcohol, ether 
and acetone extracts of honey (Vergé 1951), and Gonnet & Lavie (1960) concluded antibacterial 
components were derived from phytochemicals present in the nectar source. The origin of the non-
peroxide activity has been examined, and the proposals of lysozyme activity (Mohrig & Messner 
1968), pinocembrin (Bogdanov 1984), flavonoids and phenolic acids (Russell et al. 1990; Wahdan 
1998; Weston et al. 1999) have been dismissed, as the suggested active components are either too 
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dilute to account for the non-peroxide antibacterial activity or are also found in non-active honeys 
(Weston 2000)146.  
A number of studies analysing the antibacterial activities of New Zealand honeys have been 
completed (by Professor Peter Molan – University of Waikato, Hamilton, NZ). Whilst many honey 
types contained significant levels of hydrogen peroxide antibacterial activity, only mānuka honey 
often contained a relatively high level of non-peroxide activity (Molan et al. 1988; Allen et al. 
1991a; Allen et al. 1991b), a unique property in the world’s honey types other than the recently 
discovered non-peroxide activity in Australian jelly-bush (Leptospermum spp.) honey. The non-
peroxide antibacterial activity was considered to be linked to the floral source (Molan & Russell 
1988). However, mānuka honey samples demonstrated a considerable range of non-peroxide 
antibacterial activity, with a typical agar diffusion assay study reporting a mean antibacterial 
activity equivalent to 18.6% w/v phenol for 19 L. scoparium honey samples, with a significant 
standard deviation of 8% w/v phenol (Allen et al. 1991a). The variability was initially attributed to 
sample misidentification or processing differences (Allen et al. 1991a), and later a regional 
difference in phytochemical composition or concentration (Molan 1995). For the purpose of 
indicating the antibacterial activity for the consumer Professor P. Molan named the non-peroxide 
antibacterial activity of mānuka honey UMF® (Unique Mānuka Factor). The UMF® units of 
antibacterial activity used commercially are non-peroxide antibacterial activity equivalent to that of 
w/v% phenol on a standardised antibacterial agar diffusion assay using Staphlococcus aureus 
(NCTC 6571) as the control test organism, established by Allen et al. (1991a). Therefore, mānuka 
honey with a higher UMF® rating has a greater antibacterial effect and, is consequently more 
desirable for the production of therapeutic goods. UMF® 12+ mānuka honey is marketed for 
medical usage, however the UMF® 16+ honeys are obviously increasingly sought-after146.  
Identification of the components of mānuka honey confirmed the constituents are different from 
those found in the antibacterial L. scoparium essential oil (Tan et al.1988). The antibacterial activity 
of the essential oils is principally ascribed to the triketones, which are not present in the honey. The 
identified mānuka honey phytochemical components are similar regionally throughout New 
Zealand (Tan et al. 1989; Wilkins et al. 1993; Weston et al. 2000). There is a difference in the 
spectrum of antibacterial action of mānuka honey and other honeys in studies that determined the 
minimum inhibitory concentrations for species of bacteria. Some wound-infecting bacteria were 
found to be more sensitive to mānuka honey than a honey with activity due to hydrogen peroxide, 
and other species vice versa (Willix et al. 1992). Methicillin-resistant Staphylococcus aureus 
responded to the same concentrations of mānuka honey and a honey with activity due to hydrogen 
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peroxide, yet vancomycin-resistant Enterococcos faecium required approximately double the 
concentration of the peroxide honey to be inhibited compared with the mānuka honey (Cooper et al. 
2002). Furthermore, hydrogen peroxide antibacterial activity of honey is not effective against all 
bacterial species; Heliobacter pylori was inhibited by an application of mānuka honey but was not 
inhibited by a peroxide honey (Al Somal et al. 1994)146. 
The recognition of the therapeutic value of mānuka honey has led to the development of an 
extensive range of medical products. Initially mānuka honey was prepared for the retail therapeutic 
market; however subsequent development for wound management (Molan 1999c) has established 
mānuka honey as an accepted topical treatment for wounds (Cooper 2004). Particular effectiveness 
is displayed by wound dressings impregnated with mānuka honey in treating burns, ulcers, skin-
grafts, and skin or muscle infections containing antibiotic-resistant strains of bacteria, and several 
honey items produced for wound care have been approved by the regulatory health authorities in 
Australia, Canada, and the European Union member states (Molan & Betts 2004)146. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure . The Leptospermum scoparium fruits of both wild and cultivated plants part of the 
indigenous flora of New Zealand (own pictures taken on 4th Dec 2017 – New Zealand 
summertime).  
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Approximately 8000 tonnes of honey is harvested by apiarists annually in New Zealand. The 
principal monofloral honey types are derived from nine plant families. Five families represent the 
indigenous flora; and the honey is marketed under the common names of mānuka, kānuka, rātā, 
pōhutakawa, (Myrtaceae); rewarewa (Proteaceae); kāmahi (Cunoniaceae); tāwari 
(Escallioniaceae); and honeydew (Nothofagaceae). Cockayne (1916) recognised at an early date 
Leptospermum scoparium as a major source of honey produced by the introduced honeybee, 
reflecting both the abundance of the plant and the surplus nectar production. L. scoparium is widely 
distributed throughout New Zealand and, is often described as a dominant member of the 
indigenous flora (Wardle 1991). Consequently, mānuka honey is harvested throughout the country. 
Mānuka honey has a very distinct flavour, colour and consistency, and accordingly a unique set of 
physical characteristics that are clearly different from other honey types harvested in New Zealand. 
The colour is described as dark cream to dark brown, the aroma an aromatic damp earth, with a 
slightly bitter mineral flavour. Until recently mānuka honey was used solely for culinary purposes. 
An increasing percentage of the mānuka honey harvested annually is used for the manufacture of 
therapeutic goods. This use has emerged within the last five years, after the medical effectiveness of 
mānuka honey first became apparent and was confirmed by medical trials146.    
 
 
 
 
 
 
 
 
 
 
 
           
Figure . The Leptospermum scoparium flower, the white one is typical of wild plants and the red one 
of cultivated plants both part of the indigenous flora of New Zealand (own pictures).  
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Figure . The Glasshouse Compound of the Dept. of Biological Sciences of University of Waikato, 
Hamilton, NZ where Leptospermum scoparium plants are cultivated (own pictures).  
Figure . The Leptospermum scoparium plants blooming in New Zealand spring time (October 2017) 
at University of Waikato, Hamilton, NZ. Courtesy of Stevie Noe PhD candidate at University of 
Waikato, Hamilton, NZ.  
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3.2.2.  EXPERIMENTAL      
It has been reported by Prof. Dee Carter – School of life and environmental sciences, University of 
Sydney AUS, that one of the most common and persistent therapeutic uses of mānuka honey has 
been as a wound dressing due to its antimicrobial properties. Honey is usually derived from the 
nectar of flowers and produced by bees, most commonly the European honey bee Apis mellifera 
and, it is a complex mix of sugars, amino acids, phenolics and other substances. Phenolics act as 
antioxidants and may be responsible for anti-inflammatory and wound-healing properties of honey, 
these phenolic compounds with potential antimicrobial activity are usually present in darker 
coloured honeys. Honey types derived from different flowering plants vary substantially in their 
ability to kill bacteria, in fact it can profoundly alter the size and shape of bacterial cells, although 
the extent of this varies in different bacterial species. Mānuka honey has been tested in vitro on a 
diverse range of pathogens, particularly those that can colonize the skin, wounds, and mucosal 
membranes, where topical honey treatment is possible. Tests revealed that mānuka honey can 
effectively inhibit problematic bacterial pathogens like Pseudomonas aeruginosa, Escherichia coli, 
Proteus mirabilis, Streptococcus and Staphylococcus species (MRSA included), Enterococcus 
faecalis and many moreDee A Carter 2016.  
It is widely clear that pressure and temperature are important environmental variables influencing 
bacteria life. It has been examined by Vanlint et al. in 2011 how readily Escherichia coli – a 
nonsporulating and mesophilic bacterium, could build up resistance to extremes of temperature or 
pressure within a very short evolutionary time scale. This bacterium revealed its own potential to 
survive under exposure to high temperature or pressure, in fact Escherichia coli might adapt to 
lethal heat or high pressure – extending into the GPa range, two of the most important and general 
physical constrains on life. While heat resistance could only marginally be increased, experimental 
data show that piezoresistance could readily and reproducibly be extended into the GPa range, 
thereby greatly exceeding the currently recognized maximum for growth or survival. Results 
obtained in this study using the diamond-anvil cell (DAC) and the application of laser heating, 
revealed that the developed heat resistance was only marginal, shifting the upper survival 
temperature by approximately 1.03-fold from 58.5 to 60.0°C. However, the developed 
piezoresistance was extraordinary, and the upper pressure limit for survival readily increased at 
least 3-fold from 600 MPa to 2 GPa. Consequently, the first irrevocable evidence of microbial 
survival at ≥2 GPa has been experimentally demonstrated. [ ] It is equally clear that according to 
Hwang et al. 2016,  Escherichia coli has been killed by a polyurethane with incorporated Ag NPs 
only (coming from a citrate-capped silver NPs solution) that exhibited a very strong antimicrobial 
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activity after 24 h of incubation under dark conditions reducing the number of viable bacteria below 
the limit of detection (P-value < 0.01, detection limit: below 102 CFU mL-1)59.  
 
 
 
 
 
 
 
   
 
 
 
 
 
 
Dr S. Blair – University of Technology of Sydney and Prof R. Cooper – Cardiff Metropolitan 
University, made respectively some attempts to generate honey-resistant strains in the laboratory 
that have not been successful and there also have been no reports of clinical isolate with acquired 
resistance to mānuka honey.[x+y] Furthermore, in vitro studies combining therapeutically approved 
mānuka honey with antibiotic agents conducted by Prof R. Cooper in 2012 revealed a synergistic 
effect with oxacillin, tetracycline, imipenem, and mupirocin against the growth of an MRSA strain. 
[ ] The presence of a sub-inhibitory concentration of mānuka honey in combination with oxacillin 
restored the MRSA strain to oxacillin susceptibility due to the down-regulation of mecR1 (a protein 
that encodes an MRSA-specific penicillin-binding protein known as PBP2A) as a result of a 
mechanism of honey synergy. [ ] Strong synergistic activity between mānuka honey and rifampicin 
against multiple S. aureus strains, including clinical isolates and MRSA strains, has been found by 
 
 
 
Figure . The bacterium Escherichia coli 
(Enterobacteriaceae family).   
It is a Gram-negative, facultatively 
anaerobic, rod-shaped, coliform bacterium 
of the genus Escherichia that is commonly 
found in the lower intestine of warm-
blooded organisms. Most E. coli strains are 
harmless, but some serotypes can cause 
serious food poisoning in their hosts.  
Source: Google Library, PubMed – NCBI.   
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P. Müller – University of Technology of Sydney in 2013 and the presence of mānuka honey 
prevented the emergence of rifampicin resistance in vitro. This study also revealed that in this case 
the MGO (methyl glyoxal – it was identified in 2008 as the responsible of the “non-peroxide 
activity” of mānuka honey. It results from the spontaneous dehydration of its precursor 
dihydroxyacetone, DHA, a naturally occurring phytochemical found in the nectar of flowers of 
Leptospermum scoparium and some related Leptospermum species native to New Zealand and 
Australia) was not responsible of the powerful synergy. [ ] 
The Manuka grading: UMF and MGO are the most commonly used grading systems that convey 
the medicinal quality of the manuka honey. UMF grades start at 5+ and go as high as 25+ and MGO 
starts at 30+ and goes above 800+. Grades below UMF 10+ don’t have significant levels of 
antibacterial activity. UMF 10+ is the minimum grade of manuka honey with meaningful levels of 
antibacterial activity and has been shown to be effective at inhibiting the growth of a variety of 
bacteria species. Hence, a UMF 10+ manuka honey is recommended for general first aid. The Lund 
University researchers (Sweden) demonstrated that bacteria from bees can be a possible alternative 
to antibiotics. They have identified 13 bacteria strains, particularly living lactic acid bacteria, found 
in fresh honey that have potent antimicrobial properties, these strains found in fresh honey produce 
a multitude of active antimicrobial compounds. The bacteria healed both severe human infections in 
the laboratory, and persistent wounds in horses for which other treatments had failed. The living 
lactic acid bacteria found in fresh raw honey is not found in processed store-bought honey. Manuka 
honey containing Unique Manuka Factor (UMF) can effectively treat resistant skin infections as 
well as large wounds that can’t be repaired surgically. [ ]  
 
 
 
 
 
 
 
  
Figure . The Manuka honey grading system, courtesy of Comvita NZ Ltd. – Paengaroa NZ 
and Manuka Health NZ Ltd. – Te Awamutu NZ 2017.  
102 
 
 
 
 
 
 
 
 
 
  
 
The Manuka bush: Maori used L. scoparium for food, medicine, and timber. Pia manuka, the sugary 
gum found occasionally on young branches, was considered a delicacy and given to infants, or was 
used to alleviate coughs in adults (Crowe 1981). Brooker et al. (1987) listed a number of traditional 
medicinal uses. A decoction of leaves was taken, applied as a salve, directly chewed, or the vapours 
inhaled. The bark was used in a similar way to alleviate bronchial complaints. The tough wood was 
harvested for implement making, and a review of museum artefacts illustrated seven tools made 
from the plant’s timber (Cooper & Cambie 1991). The first recorded European use was during 
James Cook’s voyages, when L. scoparium leaves were initially used as a tea substitute, and later 
employed as an antiscorbutic in brewing beer (Cooper & Cambie 1991). Whalers continued to rely 
upon L. scoparium as a tea substitute (Brooker et al. 1987), giving rise to tea tree as a common 
name, and early settlers became so attached to the concoction that the importation of Chinese tea 
was considered unnecessary by one author (Crowe 1981). L. scoparium has continued to be valued 
for firewood and charcoal and, is often used for smoking fish.  
 
 
 
 
 
Figure . The extraordinary healing properties of Manuka Honey, courtesy of Dr Becker – Chicago, USA.  
 
Figure . The Manuka bush, L. scoparium in its 
own environment New Zealand. Courtesy of 
Manuka Health NZ Ltd. – Te Awamutu NZ 
2017.  
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The hydrogen peroxide that is formed in honey by an enzyme the bees add, and sometimes also 
particular phytochemicals from the nectar or sap, give honey antibacterial activity that is sufficient 
to be effective in clearing infection from wounds. The phytochemicals also give honey its 
antioxidant activity which is also important in wound care, acting to decrease inflammation. With 
the widespread resistance to antibiotics developing in bacteria, it is now being 'rediscovered', and in 
many cases is proving to give better results than modern wound-care products. It has the advantage 
of providing moist healing conditions without the risk of bacterial growth, preventing adhesion of 
dressings to wound tissues, giving rapid removal of pus, dead tissue, and debris from wounds, 
decreasing inflammation and thus decreasing swelling, pain and exudation of serum and preventing 
scarring, and speeding up the growth of tissues to repair wounds. (Molan 2006).  
 
 
 
 
 
 
 
 
 
 
 
Dr med. Arne Simon from the Paediatric Haematology and Oncology, Children’s Hospital Medical 
Centre, University of Bonn (Germany) reported the following case: five years ago, a 12-year old 
patient was submitted to our unit. Doctors at another hospital had removed an abdominal 
lymphoma, leaving an open drainage site on his abdomen. On admission, his wound was infected 
with methicillin-resistant Staphylococcus aureus (MRSA). In order to avoid nosocomial spread, the 
patient was immediately isolated, a difficult situation for the child to comprehend with significant 
additional costs from the perspective of the hospital. Although the patient was scheduled to receive 
Figure . The wound healing power of Manuka honey, courtesy of Lund University researchers (Sweden). 
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chemotherapy, treatment could not commence until the infection cleared. The wound was treated 
with a local antiseptic (octenidin) for 12 days. Since no improvement occurred, we decided to use 
an Australian medical honey (MedihoneyTM), which contains leptospermum honey, a type with 
excellent in vitro activity against MRSA. The wound was free of bacteria two days later, and the 
chemotherapy against the underlying illness could be started. (Arne Simon 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
As well as inhibiting planktonic bacterial cells, mānuka honey – as experimentally demonstrated, 
can also disperse, and kill bacteria living in biofilms (e.g. MRSA and P. aeruginosa in biofilm). 
Biofilms are communities of cells that are generally enclosed in a self-produced extracellular matrix 
and found adhering to surfaces, including wounds, teeth, mucosal surfaces, and implanted devices. 
Microbes resident in a biofilm are protected from antimicrobial agents, antibiotics, and can cause 
persistent and chronic infections. In 2012 it has been found that mānuka honey disrupts cellular 
aggregates and prevents the formation of biofilms of pathogen bacteria like Pseudomonas 
aeruginosa, Staphylococcus aureus, Streptococcus mutans and, shows also an antiviral effect 
against varicella-zoster virus (the cause of chicken pox and shingles) and influenza.  [Maddocks 
2012, Roberts 2012]  
 
Figure . The wound healing power of Manuka honey, courtesy of Department of Biological Sciences, 
University of Waikato, Hamilton, New Zealand.  
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Foto usi del manuka …… 
 
 
 
 
 
 
An important part of my research project has been focused on biofilms and their pathogenicity. The 
first one I studied, with the kind help of Prof. E. Sapi – University of New Haven USA, has been 
the Pseudomonas aeruginosa biofilm.  
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3.2.3.  CONCLUSION   
In ancient history the Egyptians, Assyrians, Chinese, Greeks and Romans all used honey, in 
combination with herbs and on its own, to treat wounds (Zumla and Lulat, 1989). Aristotle (350 
BC) wrote of honey being a salve for wounds (Aristotle, 1910), and Dioscorides (c.50 AD) wrote of 
honey being "good for all rotten and hollow ulcers" (Gunther, 1934). The usage of honey for wound 
care has continued throughout all ages, it being displaced from common use in the medical 
profession when antibiotics came into use in the 1940s. In recent times honey has been 
`rediscovered' by the medical profession (Zumla and Lulat, 1989), possibly because the 'antibiotic 
era' is coming to an end as increasing numbers of bacterial strains develop resistance to antibiotics.  
KIWI  
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